MCC-14-10739
[STUDY_ID_REMOVED]
Adoptive Immunotherapy in Patients with Relapsed Hematological Malignancy: Effect of 
Duration and Intensity of Early GVHD Prophylaxis on Long-Term Clinical Outcomes
IRB Version Date: 11/24/2021
Version #4 Version Date 11/24/2021  Cover  Page  (continued)  
Biostatistician  
Roy T. Sabo,  PhD 
Virginia  Commonwealth University  
Department  of Biostatistics  
PO Box  980032  
Richmond,  VA 23298- 0032 
Phone:  804-828-3047  
Fax: 804-828-8900  
Email:  rsabo@vcu.edu  Study Coordinator  
Catherine H. Roberts, PhD  
VCU Massey Cancer Center  
Bone Marrow Transplant Program  
1300 East  Marshall  Street  
PO Box  980157  
Richmond,  VA 23298- 0157 
Phone:  804-828-1292  
Email:  croberts2@vcu.edu  
IND-Exempt  
MCC  Protocol  #: MCC -14-10739  3 Version #:3  
Version  Date:  09/22/2021  TABLE  OF CONTENTS  
REVISION  HISTORY  ..................................................................................................................6  
LIST  OF ABBREVIATIONS  ........................................................................................................8  
STUDY SCHEMA  .......................................................................................................................9  
1 BACKGROUND ......................................................................................................... 10 
1.1 I NTRODUCTION  ....................................................................................................................................... 10 
1.2 R ATIONALE AND  PREVIOUS WORK  .................................................................................................... 10 
1.3 P RELIMINARY  DATA ............................................................................................................................... 12 
1.4 P ROPOSED STUDY  ................................................................................................................................ 16 
1.5 I NVESTIGATIONAL REGIMEN  ................................................................................................................ 17 
1.6 P OTENTIAL RISKS AND  BENEFITS OF  THE INVESTIGATIONAL REGIMEN ..................................... 18 
1.7 C ORRELATIVE STUDIES  ........................................................................................................................ 18 
2 OBJECTIVES  ............................................................................................................. 19 
2.1 P RIMARY  OBJECTIVE ............................................................................................................................ 19 
2.2 S ECONDARY  OBJECTIVES .................................................................................................................... 19 
2.3 E XPLORATORY  OBJECTIVES ............................................................................................................... 19 
3 STUDY  DESIGN  ......................................................................................................... 20 
3.1 G ENERAL DESCRIPTION ....................................................................................................................... 20 
3.2 P RIMARY  ENDPOINT  .............................................................................................................................. 20 
3.3 S ECONDARY  ENDPOINTS  ..................................................................................................................... 20 
4 PATIENT  SELECTION ............................................................................................... 21 
4.1 I NCLUSION CRITERIA ............................................................................................................................. 21 
4.2 E XCLUSION CRITERIA  ........................................................................................................................... 22 
5 STUDY  ENTRY  AND  WITHDRAWAL PROCEDURES  .............................................. 22 
5.1 S TUDY  ENTRY  PROCEDURES  .............................................................................................................. 22 
5.2 R ANDOMIZATION PROCEDURES  ......................................................................................................... 23 
5.3 S TUDY  WITHDRAWAL  ............................................................................................................................ 23 
6 TREATMENT PLAN  ................................................................................................... 23 
6.1 T REATMENT RANDOMIZATION  ............................................................................................................. 23 
6.2 HLA TYPING  ........................................................................................................................................... 24 
6.3 P ERIPHERAL BLOOD STEM  CELL (PBSC)  MOBILIZATION  ............................................................. 24 
6.4 P REPARATIVE REGIMEN ....................................................................................................................... 24 
6.5 I NFECTION PROPHYLAXIS  .................................................................................................................... 25 
6.6 T RANSPLANT .......................................................................................................................................... 25 
6.7 GVHD P ROPHYLAXIS  ........................................................................................................................... 26 
6.8 P OST-TRANSPLANT CYTOK INE SUPPORT ......................................................................................... 27 
6.9 T REATMENT OF ACUTE GVHD  ...................................................................................... 28 
6.10 P OST-TREATMENT  EVALUATION ........................................................................................................ 28 
6.11 M ANAGEMENT  OF MIXED  CHIMERISM /RELAPSE ............................................................................. 28 
6.12 G RAFT  FAILURE  ..................................................................................................................................... 29 
6.13 A DDITIONAL TREATMENT MODALITIES .............................................................................................. 29 
6.14 G ENERAL CONCOMITANT  MEDICATION AND SUPPORTIVE CARE GUIDELINES  ......................... 29 
MCC  Protocol  #: MCC -14-10739  4 Version #:3  
Version  Date:  09/22/2021  6.15 FOLLOW -UP PERIOD  ............................................................................................................................. 29 
7 DOSING DELAYS/DOSE MODIFICATIONS  .............................................................. 30 
8 ADVERSE EVENTS:  DEFINITIONS  AND  REPORTING  REQUIREMENTS  .............. 30 
8.1 D EFINITIONS  ........................................................................................................................................... 30 
8.2 K NOWN  AES RELATED TO  MMF,  GM-CSF,  AND G-CSF ................................................. 32 
8.3 R ECORDING  AES, SAE S, AND UPS .................................................................................................. 32 
8.4 T IME PERIOD AND GRADE OF AE C APTURE  .................................................................................... 32 
8.5 AES REQUIRING  EXPEDITED REPORTING ........................................................................................ 32 
8.6 E XPEDITED REPORTING  PROCEDURES  FOR SAE S, AND UPS .................................................... 33 
9 PHARMACEUTICAL  INFORMATION  ........................................................................ 34 
10 MEASUREMENT  OF EFFECT  ................................................................................... 34 
10.1 E NGRAFTMENT  ....................................................................................................................................... 34 
10.2 C OMPLETE  REMISSION ......................................................................................................................... 34 
10.3 L ENGTH  OF RELAPSE -FREE/DLI-FREE SURVIVAL AND SURVIVAL .............................................. 34 
10.4 T REATMENT FAILURE  ............................................................................................................................ 34 
10.5 R ELAPSE FROM  REMISSION ................................................................................................................ 35 
10.6 GVHD S TAGING  AND GRADING  ......................................................................................................... 35 
11 CORRELATIVE  STUDIES ......................................................................................... 36 
11.1 P ARTICIPATION  IN CORRELATIVE STUDIES  ...................................................................................... 36 
11.2 P ROCESSING  AND DISTRIBUTION  OF BLOOD SAMPLES  ................................................................ 36 
11.3 B LOOD  SAMPLES FOR  CORRELATIVE STUDIES  ............................................................................... 36 
11.4 L ABELING FOR ALL BLOOD SAMPLES ................................................................................................ 37 
11.5 P ROCESSING  OF BLOOD SAMPLES .................................................................................................... 37 
12 STUDY  CALENDAR  .................................................................................................. 37 
12.1 P RIOR  TO RANDOMIZATION  ................................................................................................................. 37 
12.2 F OLLOWING  RANDOMIZATION  ............................................................................................................. 37 
12.3 S TUDY  CALENDAR ................................................................................................................................. 37 
13 STATISTICAL  CONSIDERATIONS ........................................................................... 40 
13.1 R ANDOMIZATION SCHEME  ................................................................................................................... 40 
13.2 S TRATIFICATION  FACTORS  .................................................................................................................. 41 
13.3 S TATISTICAL METHODS  ........................................................................................................................ 41 
13.4 S AMPLE  SIZE AND POWER  DETERMINATION  ................................................................................... 42 
13.5 S TOPPING CRITERIA  ............................................................................................................................. 42 
14 DATA AND SAFETY MONITORING PLAN (DSMP)  ..................................................  44 
14.1 S TUDY  TEAM .......................................................................................................................................... 44 
14.2 A UDIT  COMMITTEE  ................................................................................................................................ 44 
14.3 D ATA AND SAFETY MONITORING  COMMITTEE (DSMC)  .................................................... 44 
15 REGULATORY  COMPLIANCE  AND  ETHICS  ........................................................... 45 
15.1 E THICAL STANDARD  .............................................................................................................................. 45 
15.2 R EGULATORY  COMPLIANCE ................................................................................................................ 45 
15.3 I NSTITUTIONAL REVIEW BOARD  ......................................................................................................... 45 
15.4 I NFORMED CONSENT PROCESS  ......................................................................................................... 45 
MCC  Protocol  #: MCC -14-10739  5 Version #:3  
Version  Date:  09/22/2021   15.5 P ATIENT CONFIDENTIALITY  AND ACCESS  TO SOURCE DOCUMENTS /DATA .............................. 46 
16 DATA HANDLING  AND RECORD KEEPING  ............................................................ 46 
16.1 D ATA MANAGEMENT RESPONSIBILITIES ........................................................................................... 46 
16.2 S OURCE  DOCUMENTS  .......................................................................................................................... 46 
16.3 C ASE REPORT FORMS  ......................................................................................................................... 46 
16.4 S TUDY  RECORD RETENTION  ............................................................................................................... 47 
17 REFERENCES  ........................................................................................................... 48 
List of FIGURES  
Figure  1. Comparison of overall  survival  in ATG TBI conditioned patients  
randomized to 2 ATG doses  (P=0.7)  ........................................................................... 14 
Figure 2. (A) Absolute lymphocyte count (µL-1) recovery fo llowing ATG+TBI and 
either  MRD  or URD SCT;  (B) Association of early  monocyte recovery  with 
late lymphocyte recovery  ............................................................................................  15 
Figure 3. Overview  of the randomized temporal  variation of GVHD prophylaxis  and 
randomized agent  for cytokine support  ....................................................................... 27 
Figure 4. Event (Engraftment Failure, Day 100 TRM, and Severe Engraftment  
Syndrome)  Frequency  Threshold for Applying  Stopping  Criteria  at Patient  
Accrual  Milestones  ..................................................................................................... 43 
Figure  5. Event  (GVHD)  Frequency  Threshold for Applying Stopping Criteria  at 
Patient  Acc
rual Milestones  ..........................................................................................  43 
 
 
List of TABLES  
Table 1. Expedited Reporting  Requirements  ............................................................................. 33 
Table 2. GVHD Staging  ............................................................................................................. 35 
Table  3. GVHD Grading ............................................................................................................ 36 
Table 4. Study -Required Tests and Assessments ..................................................................... 38 
Table 5. Early  Stopping Criteria  ................................................................................................. 43 
MCC  Protocol  #: MCC -14-10739  6 Version #:3  
Version  Date:  09/22/2021  REVISION HISTORY  
Version  2, Version  Date  06/23/2017  
•The date and version number were updated on the cover page and throughout the
protocol.
•Dr. Gary  Simmons  was added as a Co-Investigator on  the cover page.
•A Revision  History  page was added.
•The List of Abbreviations  was updated.
•Clarifications were made in the Background in Section 1.1 and text regarding G -CSF and
GM-CSF was re-arranged in Section 1.2.
•A study goal of comparing the survival rate of patients with multiple myeloma in either
study cohort with historical control patients was added to the study. Text was added in thefollowing sections to address this goal: Rationale (Section 1.2
); Exploratory Objectives
(Section 2.3.5 ); and Statistical  Considerations  (Sections  13.3.3 ).
•The secondary  endpoints  (Section 3.3.1 ) were  rearranged  to improve  their organization.
•Text describing the stratification factors based on diagnosis was revised in the Schema
and in Sections  1.4, 3.1, and 13.2 to include the malignancies added in eligibility (see
below).
•The types of eligible hematologic malignancies were expanded to include patients with
acute lymphocytic leukemia, chronic myelogenous leukemia, and myelodysplastic
syndrome (Section 4.1.1 ).
•The note regarding HLA -matched stem cells in unrelated donors was clarified
(Section 4.1.4 ).
•The age of the eligible  patient  population was expanded to include patients  with an age of
40-49 years  (Section 4.1.5 ).
•The note regarding substitutions for infection prophylaxis was expanded to allow
substitutions if  toxicities  develop (Section 6.5).
•The instructions regarding tacrolimus were revised to allow adjustment in target tacrolimuslevels  for drug toxicity  (bullet  1, Section  6.7.1
).
•The instruction regarding the duration of MMF- 15 and MMF- 30 was clarified (Sections  6.8,
6.8.1 , and 6.8.2 ).
•The description regarding relapse prevention interventions was revised to allow relapseprevention therapy to be given after day 60 in patients who are at high risk for relapse(Section 6.11.1
).
•Exceptions to the requirement for recording AEs (AEs expected with stem cell transplant)
were  added in Section 8.4.
•The relapse criteria text in Section 10.5.3  was revised to include the malignancies added
in the inclusion criterion in Section 4.1.1  as noted  above.
MCC  Protocol  #: MCC -14-10739  7 Version #:3  
Version  Date:  09/22/2021   • The study calendar was corrected by removing 2 time points for collection of flow  
cytometry  samples  from Table 4  (row 22, columns  2 and 3). 
• The permitted window of time for tests/assessments was revised in footnote C of  Table 4  
to provide more  flexibility  after 6 months.  
• Text was added in footnote  P of Table 4 to explain the purpose of pre -transplant  
genotyping  for chimerism  determination.  
 
Version  1, Version  Date  07/23/2015  
 
Initial version of the protocol.  
MCC  Protocol  #: MCC -14-10739  8 Version #:3  
Version  Date:  09/22/2021   LIST OF ABBREVIATIONS  
 
AE adverse  event  
ALL acute  lymphocytic  leukemia  
ALT alanine  aminotransferase  
AML acute  myelogenous  leukemia  
AST aspartate  aminotransferase  
ATG rabbit,  anti-thymocyte  globulin  (Thymoglobulin;  Sanofi -Aventis)  
AUC  area under  the curve  
BID twice  per day 
BMT  bone  marrow  transplant  
BP blood  pressure  
CIBMTR  Center  for International  Blood  and Marrow  Transplant  Research  
CML  chronic  myelogenous  leukemia  
CRF case  report  form 
CTCAE  v4.0 Common  Terminology  Criteria  for Adverse  Events  Version  4.0 
cGVHD  chronic  graft versus  host disease  
ddCD3  donor -derived  CD3+ (cell count)  
DLCO  diffusing  capacity  of the lung for carbon  monoxide  
DLI donor  lymphocyte  infusion  
DSMC  Data  Safety  and Monitoring  Committee  
FDA Food  and Drug  Administration  
FEV1  forced  expiratory  volume  in 1 second  
G-CSF granulocyte  colony  stimulating  factor  
GM-CSF granulocyte  macrophage  colony  stimulating  factor  
GVHD  graft versus  host disease  
HCT hematopoietic  cell transplant  
HL Hodgkin  lymphoma  
HLA human  leukocyte  antigen  
IBW ideal  body  weight  
MCC -VCUHS  Massey  Cancer  Center -Virginia  Commonwealth  University  Health  System  
MDS  myelodysplastic  syndrome  
MM multiple  myeloma  
MMF -15 mycophenolate  mofetil  – 15 day duration  
MMF -30 mycophenolate  mofetil  – 30 day duration  
MRD  matched  related  donor  
NHL Non-Hodgkin  lymphoma  
OHRP  Office  for Human  Research  Protections  
PBSC  peripheral  blood  stem  cells 
PO by mouth  
RIC reduced  intensity  conditioning  
SAE serious  adverse  event  
SCT stem  cell transplantation  
TBI total body  irradiation  
TRM  transplant -related  mortality  
ULN upper  limit of normal  
UP unanticipated  problem  
URD  unrelated  donor  
VCU  Virginia  Commonwealth  University  
WBC  white  blood  cell 
WCBP  woman  of childbearing  potential  
MCC  Protocol  #: MCC -14-10739  10 Version #:3  
Version  Date:  09/22/2021   1 BACKGROUND  
1.1 Introduction  
 
The last decade has seen allogeneic stem cell transplantation (SCT) evolve from a single 
intense therapeutic intervention in young healthy individuals, to a series of adoptive 
immunotherapy interventions resulting in disease control in older individuals with 
comorbidities ( 1-8). In this study, we will utilize a regimen combining low dose total body  
irradiation (TBI) and rabbit anti- thymocyte globulin (ATG; Thymoglobulin, Sanofi -Aventis)  
to facilitate SCT with human leukocyte antigen (HLA) -matched related and unrelated 
donors ( 9-13). Based on the hypothesis that early treatment interventions have significant  
late effects in allogeneic SCT, a simple intervention, varying the duration of intense  
immunosuppression following SCT, will be investigated in this study. Patients will receive 
graft versus host disease (GVHD) prophylaxis using 2 different immunosuppressive 
regimens with tacrolimus + mycophenolate mofetil (MMF). Patients randomized to the investigational cohort will receive MMF for 15 days following SCT with cytokine support  
using granulocyte macrophage colony stimulating factor (GM -CSF) beginning on post - 
transplant day 4. Patients randomized to the control cohort will receive MMF for 30 days  
following SCT with cytokine support using granulocyte colony stimulating factor (G -CSF)  
beginning on post -transplant  day 4. 
 
Despite the advancements made in allogeneic SCT over the past few decades, patient  
survival following allogeneic SCT remains highly unpredictable. The ability to identify  
unique immunologic profiles for patients with next generation sequencing and recently  
discovered patterns  in genetic  variation relating  to donors  and recipients  may be critical  
tools in the process of furthering the understanding of patient prognosis following  
allogeneic SCT. A dynamical modeling system approach will be utilized to explore the validity of predicting patient outcomes post -transplant based on analysis of individual  
immune  reconstitution in a trial comparing  temporal  variation of GVHD  prophylaxis.  
 
1.2 Rationale  and Previous  Work  
 
The rationale for this study is based on the recent findings that transplant outcomes are determined by the rate of T -cell reconstitution and lymphoid recovery in the first 2 months  
of SCT.  
 
Donor -derived T cells exert a powerful anti- malignancy effect in patients with acute and 
chronic myeloproliferative and lymphoproliferative disorders. However, these disorders  
largely affect an elderly population where patients are unable to tolerate complications of  
SCT resulting from alloreactivity between donors and recipients, specifically GVHD.  
Adoptive immunotherapy interventions, such as reduced intensity conditioning and SCT 
followed by DLI, have resulted in disease control in older individuals. While this has  
enabled clinicians to pursue SCT in large numbers of elderly patients with hematological  
malignancy, GVHD remains a major complication of transplantation and continues to take 
a heavy  toll on these  patients.  
 
Further complicating matters is the unpredictability in the likelihood of GVHD developing in 
HLA-matched individuals transplanted using identical preparative regimens. Ability to 
predict  clinical outcomes  in patients  as they go through the transplant  process  would be a 
MCC  Protocol  #: MCC -14-10739  11 Version #:3  
Version  Date:  09/22/2021   major advance in the clinical management of these patients. Clinical medicine is replete 
with phenomenon where interventions produce predictable results in a majority of  
instances. Examples of this may be seen most readily  in cardiovascular and pulmonary  
medicine, where administration of a beta- blocker may slow down a tachycardic rhythm or  
administration of a beta -agonist relieves bronchospasm. In both these instances,  
administration of a drug, which interrupts or facilitates passage of an ionic current across  
cell membranes, yields an outcome, which may be predicted with a fair measure of  
confidence in most patients. Indeed these systems may be considered analogous to dynamical systems often encountered in the physical sciences, where a measurable change of state is produced over time as the variables determining that state undergo 
change, for example, change in velocity as an object accelerates. Thus, by reducing the 
excitability of the cardiac conduction system, beta -antag onists can stabilize a chaotic  
cardiac rhythm  and restore  normal sinus  rhythm.  
 
Unlike the clinical situations described above, survival likelihood following allogeneic SCT  
remains probabilistic despite decades of clinical refinement and advances. Attempts  to 
predict outcomes in individuals undergoing this life- saving, albeit dangerous, procedure are  
limited to calculations of survival odds derived from population -based studies. Although 
generalities such as HLA matching, availability of a family donor, application of certain  
pharmacological interventions, or others do predict for better results when cohorts of  
patients are examined, foretelling the course of an individual transplant recipient remains  
impossible. This has led to stochastic modeling of transplant interventions, which though 
valuable in identifying factors contributing to improved population outcomes, fails to yield 
mechanistic insights into transplant immunobiology when examined in an ‘isolated’ donor - 
recipient  pair. 
 
Recently, application of  next generation sequencing has led to the unveiling of a 
remarkably complex immune repertoire in allogeneic transplant recipients following  
transplantation. While on the surface this complexity is chaotic and disorganized, it does  
offer an excellent opportunity to explore the unique patterns that may characterize each individual’s immunologic repertoire during reconstitution ( 14
). Furthermore, the genetic  
variation demonstrated between individual transplant donors and recipients displays a corresponding degree of complexity to that of the post -transplant immune repertoire,  
making it entirely plausible that the latter is predicated upon the former (
15, 16). If thi s is 
the case, then SCT may be considered to be a dynamical system; as such, SCT may be susceptible to the interpretation and analysis applicable to a dynamical system if all the 
variables determining the evolution of the system following SCT can be identified and 
quantified (
17). 
 
Several lines of evidence suggest that early interventions during the course of SCT have a profound influence on long- term outcomes in transplant recipients. This is analogous to 
certain types of dynamical systems, where minor modifications in the state of the system at an early time point can produce large variation in later outcomes. Extrapolating this logic to SCT suggests that it is likely that interventions made early in the course of transplant may  
have profound effects on the later stages of immune reconstitution. The progression of  
immune reconstitution following SCT appears to follow the same dynamics that govern the 
growth  of biological  systems. These growth  dynamics  are described by the  logistic  
equation describing sigmoidal growth ( 18
), which models initial slow growth followed by  
exponential expansion,  eventually  culminating  in a stable  population.  The parameters  
MCC  Protocol  #: MCC -14-10739  12 Version #:3  
Version  Date:  09/22/2021   describing the lymphocyte reconstitution curve in each individual are associated with 
clinical outcomes.  
 
The next generation sequencing work done by our group also reveals a previously  
undescribed magnitude of alloreactivity potential between SCT donors and recipients. This  
provides  an explanation for drugs such as ATG that can ameliorate the risk of GVHD. In a 
recently concluded trial, our group demonstrated that it is feasible to combine ATG with low  
dose TBI. A lower dose of ATG results in reliable T -cell engraftment with low risk  of GVHD.  
However, disease relapse remains a problem and is more prevalent when the rate of  
immune reconstitution is low. The dynamical system nature of immune reconstitution would 
imply that relatively minor changes in treatments earlier in the course of SCT will result in  
significant long -term therapeutic effects in patients. Therefore, a clinical trial comparing 2 
cohorts of patients treated uniformly with a background of ATG and TBI, except for small  
differences in early post -transplant immunosuppression, would be informative in this  
regard. Further, in addition to optimizing clinical outcomes, such a study may yield important mechanistic insights into the interaction between the kinetics of immune 
reconstitution  and clinical outcomes.  
 
G-CSF (filgrastim) and GM -CSF (sargramostim) are regulatory glycoproteins that stimulate  
the proliferation, differentiation, and functional  activity of neutrophils.  While  G-CSF is a 
late-acting hematopoietin restricted to the neutrophil lineage, GM -CSF is a mult i-lineage  
hematopoietin essential for production of granulocytes, monocytes, and macrophages ( 19). 
We have recently shown that early monocyte recovery is associated with faster T -cell 
reconstitution in ATG -conditioned patients ( 20). Thus, we hypothesize that using GM -CSF 
following transplantation would enhance monocyte recovery and subsequent T- cell 
reconstitution. While experience with GM -CSF following allogeneic SCT is more limited  
than experience with G -CSF, several randomized, double- blind trials have shown 
significantly reduced time to achieve neutrophil recovery with the use of GM -CSF after  
bone marrow or peripheral blood stem cell (PBSC) transplantation ( 21-24). Additionally, a 
large meta -analysis identified no significant increase in the risk of acute or chronic GVHD  
following  treatment  with GM-CSF ( 25). 
 
A further goal of this study will be comparison of clinical outcomes achieved with allografting in patients with multiple myeloma. Allografting for myeloma is a therapeutic  
conundrum given the competing risks of disease relapse and non -relapse mortality from  
GVHD and immune compromise. Given the focus of this trial on ameliorating GVHD and 
consequently minimizing immunosuppression, it is logical that, compared to standard 
allografting approaches, myeloma patients will experience an improvement in survival  
because of the reduction in non- relapse mortality. In order to accomplish these 
comparisons, we will conduct an analysis comparing outcomes in myeloma patients  
transplanted on this trial with historical outcomes in patients matched for clinical  
characteristics, but who did not  undergo allografting.  
 
1.3 Preliminary  Data  
 
The cli nical trial we propose is based on an allogeneic SCT regimen incorporating rabbit  
anti-thymocyte globulin (ATG) and low dose (450 cGy) TBI. This regimen is based on the 
preclinical model of using anti -T-cell antibodies prior to SCT to achieve a tolerant pl atform  
on which to  perform  adoptive  immunotherapy  with DLIs.  
MCC  Protocol  #: MCC -14-10739  13 Version #:3  
Version  Date:  09/22/2021   The rationale for the use of ATG in this regimen is to facilitate engraftment and deplete 
donor T cells capable of causing acute and chronic GVHD ( 26, 27). The combination of  
ATG and TBI has further been shown to reduce GVHD by altering residual host T- cell 
subsets to favor regulatory natural killer T cells ( 12, 28). These specific T cells may  
suppress  GVHD by polarizing  donor  conventional T cells toward secretion  of 
non-inflammatory cytokines such as IL- 4 and promoting expansion of donor T regulatory  
cells.  
 
Given that reduced intensity conditioning (RIC) relies on the graft vs malignancy effect  
mediated primarily by donor T cells, there is concern the use of ATG may increase relapse 
in this setting. In 2011, a large retrospective registry analysis from the Center for  
International Blood and Marrow Transplant  Research (CIBMTR) was published ( 29). This  
analysis  examined outcomes  of adult  patients  with hematologic  malignancies  who received 
RIC from 2000 to 2007 and included 879 patients who did not receive ATG and 584 
patients who received varying doses and preparations of ATG. In the multivariate analysis,  
relapse rates  at 3 years  were  higher  in the ATG group vs non-ATG group (49%  vs. 38%,  p 
<0.01), negatively impacting overall survival. While the results of this trial raise important  
questions regarding the use of ATG in RIC, we do not believe the findings of this analysis  
can be applied to our trial design. The median dose of rabbit ATG administered to patients  
included in the CIBMTR report was high at 7mg/kg and administered closer to the time of  
stem cell infusion based on the most common conditioning regimens reported (fludarabine and busulfan, fludarabine and melphalan, and fludarabine and cyclophosphamide). The 
ATG dose proposed in our trial is lower at 5.1 mg/kg and administered early (days -9 
through -7), limiting effects on donor T cells. In a similar study of total lymphoid irradiation 
and ATG conducted by Lowsky and colleagues, ATG was administered early prior to  
allogeneic SCT on days -11 through -7. Serum levels of active ATG (capable of binding  
CD3+ T cells) were measured and were nearly undetectable on the day of transplantation 
and absent beyond day +7 ( 30
). Finally, the relapse results noted in the CIBMTR registry  
report are also limited  by the lack of data on immune reconstitution and use of DLI. 
 
The ATG+TBI regimen is followed by tacrolimus and MMF for GVHD prophylaxis. In earlier  
versions of this regimen, a schedule of ATG (10 mg/kg) given from day -10 to day -7 prior  
to blood stem cell infusion was found to yield superior T- cell recovery when compared with 
ATG administered more  proximal to  SCT (31). 
 
In a follow -up trial to determine the optimal dose of ATG, a schedule of 5.1 mg/kg delivered 
on day -9 to -7 was found to accomplish superior  T-cell engraftment  when compared  with a 
7.5 mg/kg dose in patients with hematological malignancies ( 32). In the cohorts treated to  
date using this regimen, classical onset of grade III -IV acute GVHD has not occurred, nor  
has day 100 treatment -related mortality. Higher rates of mixed chimerism and the need for  
DLI (4/19 and 10/22 in ATG5 and ATG7.5, respectively) were recorded in the higher dose 
ATG arm. Patients with higher donor -derived T -cell counts (ddCD3) at 8 weeks post - 
transplant were more likely to achieve full donor chimerism and have a lower relapse rate,  
but sustained a higher frequency of GVHD ( 33). With 41 patients enrolled in this  
randomized phase 2 trial stratified for donor type (matched related donor [MRD] [n=19] vs  
unrelated donor [URD] [n=22]), overall survival at 2 years in the 2 arms was similar  
(68±1% vs 63±1%, p=NS) ( Figure 1 ). Relapse occurred i n 32% (6/19) vs 46% (10/22) of  
the ATG5 and ATG7.5 patients,  respectively  (Chi- square  P=0.364).  
MCC  Protocol  #: MCC -14-10739  14 Version #:3  
Version  Date:  09/22/2021    
 
 
 
Figure  1. Comparison of overall  survival  in ATG TBI conditioned patients  randomized to 2 
ATG doses (P=0.7)  
 
Given the importance of donor -derived T cells in terms of clinical outcomes, the T- 
cell receptor β repertoire was studied using high throughput sequencing of the T -cell 
receptor β. This revealed that rather than a random collection of T -cell clones, the 
immune repertoire in normal donors and SCT recipients had a fractal organization.  
Furthermore, when the genomic differences between donors and recipients of SCT 
were determined using whole exome sequencing, a very large amount of protein 
coding variation was observed. This variation across the exome, when translated to  
HLA-binding oligopeptides, demonstrated a HLA -binding affinity profile that mirrored 
the T- cell repertoire organization ( 34). This observation suggests that SCT  
represents an example of a dynamical system, albeit a very complex system, where 
T-cell clonal expansion mimics population growth and may be modeled using the 
logistic equation. 
 
Absolute lymphocyte count recovery was defined as an average representation of  
T-cell clonal  recovery  and plotted for  each individual  patient  following  SCT 
(Figure 2 ). Notably, several individuals demonstrated a biphasic logistic growth 
curve. The first phase of exponential lymphocyte growth was observed coincident  
with eng raftment around day 15- 20 post -transplant and a second exponential  
growth phase was observed after cessation of MMF around day 40- 50. This is  
consistent with the observation that the day 60 ddCD3 count has prognostic  
significance. It also provides an important clue regarding the optimal timing of  
immunological  intervention following  SCT.  

MCC  Protocol  #: MCC -14-10739  15 Version #:3  
Version  Date:  09/22/2021   A. 
 
 
B. 
 
 
Figure  2. (A) Absolute lymphocyte count  (µL-1) recovery  following  ATG+TBI  and either MRD  
or URD  SCT;  (B) Association  of early  monocyte recovery  with late  lymphocyte  recovery  
In (A) of Figure 2, two periods of logistic growth are seen: from day 0- 30 when patients are 
on MMF (blue outline) and from day 20 to approximately day 120 (orange outline). Each of  
these periods demonstrates an initial phase of slow growth followed by exponential  
expansion before finally leveling out with relatively stable counts until tacrolimus is  
discontinued.  In (B) of Figure 2, two different  patterns  of monocyte  recovery  are associated 
with different  lymphocyte recovery  kinetics  (20). 

MCC  Protocol  #: MCC -14-10739  16 Version #:3  
Version  Date:  09/22/2021    
1.4 Proposed Study  
 
In this trial we will attempt to optimize post -transplant immunosuppression in a cohort of  
patients conditioned using an ATG -based regimen, with the goal of improving long -term 
immune reconstitution. This will likely reduce the risk of opportunistic infections, graft loss,  
and relapse in patients undergoing reduced intensity conditioning with a regimen 
incorporating ATG. Abbreviating the course of MMF will allow faster T- cell rec onstitution.  
Additionally, we have recently shown that early monocyte recovery is associated with 
faster T -cell reconstitution in ATG -conditioned patients. Using GM -CSF would enhance 
monocyte recovery  in patients,  potentially  improving T- cell reconstitution.  
 
In a series of trials investigating ATG use with low dose TBI, the optimal dose and schedule of ATG has been determined ( 31, 33
). In the first trial the optimal schedule for  
ATG dosing with low dose TBI was determined; in the follow -up trial the dose of ATG to be 
given  was selected.  In the proposed study  we will utilize  the regimen combining  rabbit  
anti-thymocyte  globulin  (ATG;  Thymoglobulin,  Sanofi -Aventis)  1.7 mg/kg/day  given  on day 
-9 through day -7, and 450 cGy TBI delivered in 3 fractions of 150 cGy each on day - 1 and 
day 0. SCT will be with blood stem cells or marrow from HLA -matched related and 
unrelated  donors.  
 
Based on the hypothesis that early treatment interventions have significant late effects in allogeneic SCT, the main interventions to be investigated in this study are: 1) varying the duration of intense immunosuppression following SCT and 2) administering different  
cytokines for hematopoietic reconstitution. Patients wil l receive GVHD prophylaxis with 2  
different immunosuppressive regimens using tacrolimus + MMF. Patients in the control  
cohort  will receive MMF  for 30 days  following SCT  and, in the investigational  cohort,  MMF  
will be given for 15 days post SCT. The control arm patients will receive G -CSF 5  
mcg/kg/day (filgrastim) for hematopoietic reconstitution, while the patients in the investigational  arm will receive 250 mcg/m
2/day of GM-CSF (sargramostim)  (35). 
 
An adaptive trial design will be used, with the study endpoint for adaptive allocation on the 2 study cohorts being donor -derived T -cell recovery at post -transplant day 60. Patients will 
be stratified by diagnosis (Hodgkin lymphoma [HL], Non- Hodgkin lymphoma [NHL], acute 
lymphocyt ic leukemia [ALL], and chronic lymphocytic leukemia [CLL] or multiple myeloma 
[MM] or acute myelogenous leukemia [AML], chronic myelogenous leukemia [CML], and  
myelodysplastic syndrome [MDS]) and by donor type (matched related or matched 
unrelated). Following adaptive allocation, patients will be eligible to undergo disease- 
specific relapse prevention therapies according to MCC -VCUHS BMT Program standards.  
Subsequent to this, patients will be followed for survival, relapse, GVHD, and immune 
reconstitution  endpoints.  
 
The impact of variation in the duration and intensity of early post -transplant GVHD  
prophylaxis in patients conditioned with ATG 5.1 mg/kg and low dose TBI will be studied.  
Lymphoid recovery following SCT appears to follow a bilogistic pattern with the current  
GVHD prophylaxis regimen. It appears that the one month long course of MMF following  
SCT delays T -cell reconstitution and may delay the establishment of full donor T- cell 
chimerism in ATG -based reduced intensity conditioning regimens. Because the first phase 
of exponential lymphoid expansion was  observed around the time of engraftment  and 
MCC  Protocol  #: MCC -14-10739  17 Version #:3  
Version  Date:  09/22/2021   because in the dynamical system model the very first phase of the T- cell clonal growth will  
be critical for the long -term outcome, the investigational arm will have MMF discontinued at  
day 15 to allow uninhibited growth of T-cell clonal  populations. This  will likely  be reflected 
in ddCD3 recovery at 8 weeks post SCT. Hypothetically, the relapse rate and opportunistic  
infection incidence  will be reduced in these  patients  as compared to the control  cohort.  
 
Two post -transplant outcomes will be studied in this randomized phase 2 SCT trial: clinical  
outcomes and immune reconstitution in the background of genetic variation between 
donors and recipients. The ddCD3 cell count at 8 weeks post -transplant will be used to 
adaptively allocate patients to the 2 study arms, which will compare post -transplant GVHD  
prophylaxis with MMF given for either 15 days or 30 days. As noted above, in the previous  
trials a marked increase in lymphocyte counts following the cessation of MMF was  
frequently observed. This makes it plausible that discontinuation of MMF earlier will hasten lymphocyte recovery  and lead to improved clinical  outcomes.  
 
Patients with hematological malignancies will be conditioned using ATG 5.1 mg/kg given in divided doses from day - 9 thru -7, followed by 450 cGY TBI in 3 fractions administered on 
day -1 and day 0. Blood stem cells from HLA- A, -B, -C, and - DRB1 8/8 matched related or  
unrelated donors will be provided and post -graft GVHD prophylaxis will be administered 
using tacrolimus (day -3 to day 120; tapered thereafter depending on donor -derived T -cell 
count)  and MMF.  
 
The randomization of the stratified cohorts will be between MMF 15 mg/k g administered 
twice daily from day 0 to day 30 in the control cohort (MMF- 30) and day 0 to day 15 in the 
investigational  cohort  (MMF -15). The MMF -30 arm is  similar  to the regimen  used  in 
MCC -11561 and will serve as the control arm, whereas the investigati onal arm will be  
MMF -15, where MMF will be discontinued closer to the time of myeloid engraftment.  
Patients in the investigational arm (MMF- 15) will also receive sargramostim (GM -CSF) for  
hematopoietic  reconstitution with the hypothesis  that this will lead to more  robust  monocyte  
recovery and consequently rapid lymphocyte reconstitution. Patients randomized to the control  cohort  (MMF -30) will receive filgrastim (G -CSF).  Presumably, this will result  in 
faster and more robust eventual T -cell reconstitution, helping reduce relapse and infection 
risk without  affecting  GVHD risk.  
 
1.5 Investigational  Regimen  
 
1.5.1 MMF  
 
MMF is a potent uncompetitive inhibitor of inosine monophosphate dehydrogenase and, therefore, inhibits the de novo pathway of guanosine nucleotide synthesis  
without incorporation into DNA. Because lymphocytes are critically dependent for  
their proliferation on de novo synthesis of purines, whereas, other cell types can utilize salvage pathways, the active component of MMF (mycophenolic acid [MPA])  
has potent cytostatic effects on lymphocytes. MPA also inhibits proliferative responses of T and B cell mitogens, antibody formation by B cells, and prohibits  
glycosylation  of glycoproteins that mediate  adhesion.  
 
MMF is indicated for the prophylaxis of organ rejection in patients receiving  
allogeneic  renal,  cardiac,  or hepatic  transplants.  In experimental animal  models,  
MMF  has been demonstrated to prolong the survival  of allogeneic  transplants  
MCC  Protocol  #: MCC -14-10739  18 Version #:3  
Version  Date:  09/22/2021   (e.g., kidney, heart, liver, intestine, limb, small bowel, pancreatic islets, and bone 
marrow). MMF has been extensively studied in clinical trials following bone marrow  
transplantation and has been included in GVHD prophylaxis following blood and bone marrow  transplant  for more  than 15 years.  
 
Gastrointestinal adverse reactions including diarrhea, nausea/vomiting, and mucositis have been reported. Constitutional symptoms include pain, fever,  
headache, and asthenia. Hematological toxicities, such as anemia and leukopenia,  
occur  in 25% of patients . Peripheral edema  has also been  reported.  
 
Previous clinical studies in patients after renal allografting suggested that the principal adverse reactions associated with the administration of MMF include diarrhea, leukopenia, sepsis, vomiting, and a higher  incidence of certain viral  
infections, e.g., cytomegalovirus (CMV), varicella zoster virus, and herpes simplex  
virus.  
 
1.5.2 Cytokine  Support  following SCT 
 
The cytokine to be used for hematopoietic reconstitution will be specified as part of  
the randomized treatment regimen. The investigational cohort (MMF- 15) will receive 
GM-CSF (sargramostim) to potentially provide more robust monocyte recovery and 
consequently rapid lymphocyte reconstitution. The control cohort (MMF- 30) will 
receive granulocyte colony stimul ating factor (G -CSF; filgrastim). Both colony  
stimulating  factors  have been used extensively  in the treatment  of patients  receiving  
myelosuppressive therapies since initial approval by the Food and Drug  
Administration  (FDA)  in 1991.  
 
1.6 Potential  Risks and Benefits of the Investigational  Regimen  
 
1.6.1 Potential  Risks  
 
The potential risks associated with the study design include a higher risk of acute 
and/or chronic GVHD and higher risk of engraftment syndrome in the investigational  
cohort. These potential risks are included in the stopping criteria described in 
Section 13.5. 
 
1.6.2 Potential  Benefits  
 
As described previously, reducing the intensity of the GVHD prophylaxis by  
shortening the duration of MMF will potentially result in faster and more robust  
eventual  T-cell reconstitution, helping reduce relapse and infection  risk. 
 
1.7 Correlative Studies  
 
To allow for mathematical modeling changes over time, additional blood samples for flow  
cytometry to assess monocytes, T- cell subset, B cell, and natural killer (NK) cell recovery  
will be drawn (4 mL) at 2, 6, and 10 weeks (in addition to the standard time points of 4, 8,  
12, 24, and 52 weeks). Additional blood samples will be drawn (4 mL) pre- transplant, about  
30 days and 100 days post -transplan t, and at the time of GVHD diagnosis. These will be 
processed  and stored  for future  T-cell receptor  (TCR)  sequencing.  Cryopreserved 
MCC  Protocol  #: MCC -14-10739  19 Version #:3  
Version  Date:  09/22/2021   peripheral blood mononuclear cells (PBMCs) will be obtained and stored through the VCU  
Tissue and Data Acquisition and Analysis Core (TDAAC).  
 
2 OBJECTIVES 
2.1 Primary  Objective  
 
To determine the difference in the relapse -free/DLI -free survival rate between patients  
randomized to  MMF -30 (control  cohort)  and MMF -15 (investigational  cohort)  
 
2.2 Secondary  Objectives 
 
2.2.1 To determine the difference between patients randomized to MMF- 30 (control  
cohort)  and MMF -15 (investigational  cohort)  in the following: 
 
2.2.1.1  Day 60 ddCD3  
 
2.2.1.2  Overall  survival  (OS)  
 
2.2.1.3  Rate  of acute GVHD 
 
2.2.1.4  Rate  of chronic  GVHD  
 
2.2.1.5  Rate  of opportunistic  infection  
 
2.2.1.6  Rate  of graft loss 
 
2.2.1.7  Rate  of engraftment  syndrome  
 
2.2.1.8  Rate  of achieving  donor  chimerism  
 
2.2.1.9  T-cell recovery  kinetics  following  SCT 
 
2.3 Exploratory  Objectives 
 
2.3.1 To evaluate dynamic  exposure to immunosuppressive therapies  
 
2.3.2 To determine HLA -specific alloreactivity potential between HLA -identical transplant  
recipients  
 
2.3.3 To determine  T-cell receptor  beta and alpha repertoire restoration  kinetics  following  
SCT 
 
2.3.4 To explore the association and relationship between T -cell recovery kinetics,  
dynamic exposure to immunosuppressive therapies, HLA -specific alloreactivity  
potential between HLA -identical transplant recipients, and T- cell receptor beta and 
alpha repertoire  restoration kinetics  
MCC  Protocol  #: MCC -14-10739  20 Version #:3  
Version  Date:  09/22/2021   2.3.5 To determine the difference in survival rate between patients with multiple myeloma 
in either study cohort (MMF- 15 or MMF- 30) and historical control patients with 
multiple myeloma who have relapsed but have never received an allogeneic  
transplant  
 
3 STUDY  DESIGN 
3.1 General  Description  
 
This is a randomized phase 2 trial for patients with high risk or recurrent hematological  
malignancies who are candidates for reduced intensity allogeneic stem cell transplantation.  
All transplant -related treatment interventions are performed according to standard 
transplant procedures with the exception of the duration (15 days vs 30 days) of MMF, an agent routinely included in GVHD prophylaxis. The agent used for cytokine support for the  
investigational cohort (MMF- 15) will be GM -CSF; G -CSF will be included in the treatment  
regimen for the control cohort  (MMF -30). Both cytokines are routinely used following  
allogeneic SCT.  
 
Patients enrolled in the study will undergo randomization stratifying them according to diagnosis (HL/NHL/ALL/CLL or MM or AML/CML/MDS) and donor type (matched related donor or matched  unrelated donor [MRD or URD]). A total of 60 patients will be accrued in 
the study  over a period of  5 years.  
 
3.2 Primary  Endpoint  
 
The proportion of patients with event -free survival in the investigational cohort compared to 
the proportion  of patients with event -free survival  in the control  cohort  where the 
conditional events  are the occurrence  of relapse or DLI. 
 
3.3 Secondary  Endpoints 
 
3.3.1 Secondary endpoints for the objective to determine the differences between patients 
randomized to  MMF -30 (control  cohort)  and MMF -15 (investigational cohort)  
3.3.1.1  ddCD3  counts  measured  on day 60 
3.3.1.2  Overall  survival  (days  to event)  
3.3.1.3  Diagnosis  of acute GVHD  
3.3.1.4  Diagnosis  of chronic  GVHD  
3.3.1.5  Diagnosis  of an opportunistic  infection  
3.3.1.6  Diagnosis  of graft loss 
3.3.1.7  Diagnosis  of engraftment  syndrome  
3.3.1.8  Donor  chimerism  
3.3.1.9  Number  of T cells indicating recovery  following  SCT 
MCC  Protocol  #: MCC -14-10739  21 Version #:3  
Version  Date:  09/22/2021   4 PATIENT SELECTION 
4.1 Inclusion Criteria  
 
A patient must meet all of the following inclusion criteria to be eligible to participate in the 
study.  
 
4.1.1 Any of the following high  risk or recurrent hematological  malignancies:  
• Hodgkin lymphoma (HL) 
• Non-Hodgkin  lymphoma (NHL)  
• Chronic  lymphocytic  leukemia (CLL)  
• Multiple  myeloma (MM)  
• Acute  myelogenous  leukemia  (AML)  
• Acute  lymphocytic  leukemia  (ALL)  
• Chronic  myelogenous  leukemia  (CML)  
• Myelodysplastic  syndrome (MDS)  
Note: Determination that the malignancy is high risk will be made by the  
investigator.  
 
4.1.2 Investigator determination that the patient is an appropriate candidate for reduced intensity allogeneic SCT with the standard MCC- VCUHS BMT Program regimen  
employed in this  trial 
 
4.1.3 Patients  with or without  previous  myeloablative autologous  transplant  
 
4.1.4 HLA-matched stem cell donor, either related (6/6 or 5/6 loci matched) or unrelated 
(8/8 or 7/8 loci matched)  
Note: Unrelated donors should be matched at HLA -A, -B, -C, and - DRB1 loci.  
However, a single locus mismatch will be acceptable in the event a more closely  
matched  donor  is not available.  
 
4.1.5 Age ≥ 40 to < 75 years; patients 18 to 39 years of age will be eligible only if the investigator has  determined that the patient has comorbidity(ies) precluding  
conventional allogeneic  transplantation  with full intensity  myeloablative conditioning 
 
4.1.6 Karnofsky  Performance Status  of 70-100%  
 
4.1.7 Negative  serology  for HIV 
 
4.1.8 Women who are not postmenopausal or have not undergone hysterectomy must  
have a documented negative serum pregnancy test per standard MCC -VCUHS  
BMT  Program  guidelines  
4.1.9 Ability to understand and the willingness to sign a written informed consent  
document  
MCC  Protocol  #: MCC -14-10739  22 Version #:3  
Version  Date:  09/22/2021   Note:  The consent  form must be signed  and dated prior to initiation  of SCT  
preparative treatments  (see Section  6.4). 
 
4.2 Exclusion Criteria  
 
A patient who meets any of the following exclusion criteria is ineligible to participate in the 
study.  
 
4.2.1 Previous  therapeutic radiation therapy (RT) that exceeds critical structure tolerance 
doses as  determined by a radiation oncologist  
4.2.2 Uncontrolled viral,  fungal,  or bacterial  infection  
 
4.2.3 Active  meningeal  or central  nervous  system disease 
 
4.2.4 Previous  therapy  with rabbit  anti-thymocyte  globulin  (ATG);  previous  treatment  with 
equine  ATG is allowed if  more  than 3 months ago 
Note:  Previous  myeloablative autologous  transplant  is permitted  but not required.  
 
4.2.5 Pregnancy  or breastfeeding 
 
4.2.6 Medical, psychological, or social condition that, in the opinion of the investigator,  
may increase the patient’s risk or limit the patient’s adherence with study  
requirements  
 
5 STUDY  ENTRY  AND  WITHDRAWAL PROCEDURES  
5.1 Study  Entry  Procedures 
 
5.1.1 Required Pre-Registration  Screening Tests  and Procedures  
 
Refer to the study calendar in Section 12  for the screening tests and procedures  
that are required prior to registration, and for the timing of these events relative to 
the start of the SCT preparative regimen.  
MCC  Protocol  #: MCC -14-10739  23 Version #:3  
Version  Date:  09/22/2021   5.1.2 Study  Enrollment  
 
The following are  needed for patient  registration:  
 
• Completed,  signed,  and dated eligibility  checklist  
• Signed and dated  consent  form 
 
The patient’s initial enrollment data (e.g., demographics, consent, eligibility, on 
study, treatment assignment) will be entered into the OnCore database within 24 
hours of  registration and before treatment  begins.  
 
5.2 Randomization  Procedures 
Upon registration, patients will be randomized to either the investigational cohort  
(MMF -15 with GM-CSF)  or to the control  cohort  (MMF -30 with G-CSF)  according to a 
pre-specified  randomization assignment  provided by the statistician  (see Section 13.1). 
 
5.3 Study  Withdrawal  
 
A patient  will be removed from the study  for any of the following  reasons:  
• Consent  withdrawal  for study  treatment  and study  procedures  
• If, in the opinion of the investigator,  it is in the best interest  of the patient  to do so 
• The study  has been  closed by the Principal  Investigator  
• The study  has been closed by the study  sponsor  
 
The reason for withdrawal from the study and the date the patient was removed from the study  must  be documented in the  case report  form.  
 
6 TREATMENT PLAN  
6.1 Treatment  Randomization 
 
Eligible patients who consent to participate in the study will undergo randomization 
between 2 GVHD prophylaxis  cohorts.  
 
6.1.1 MMF -15 Cohort  
 
The investigational cohort will receive MMF orally at a dose of 15 mg/kg BID from  
day 0 to day 15. GM -CSF will be administered by subcutaneous injection to support  
hematopoietic  reconstitution.  
 
6.1.2 MMF -30 Cohort  
 
The control  cohort  will receive MMF  orally  at a dose  of 15  mg/kg  BID from 
day 0 to day 30. G- CSF will be administered by subcutaneous injection to support  
hematopoietic  reconstitution.  
MCC  Protocol  #: MCC -14-10739  24 Version #:3  
Version  Date:  09/22/2021   6.2 HLA Typing  
 
All HLA typing will be confirmed according to the standard procedures of the MCC- VCUHS  
BMT  Program . 
 
6.3 Peripheral  Blood  Stem  Cell (PBSC)  Mobilization  
 
Donors  should be mobilized  using a standard  stem  cell mobilization  protocol  as follows:  
 
• Filgrastim  (G-CSF)  10 mcg/kg/day  administered by subcutaneous  injection  beginning  
on day 1 of the stem  cell mobilization  protocol  and continuing through  day 5 
 
• Apheresis  performed on days  4 and 5; a CD34+ cell dose of at least  
5 x 106 CD34+  cells/kg recipient  body  weight  will be obtained,  if possible.  
 
For unrelated donors at National Marrow Donor Program (NMDP) centers, although PBSC  
will be the first choice, bone marrow will be acceptable based on donor choice if no other  
donors are available.  
 
6.4 Preparative Regimen  
 
6.4.1 ATG 
 
All patients  will receive rabbit  ATG (Thymoglobulin,  Sanofi -Aventis)  at a dose of 
1.7 mg/kg/day for 3 days (5.1 mg/kg total). ATG will be administered intravenously  
over 10-12 hours,  starting  on day  -9 and continuing daily through  day -7. 
 
Patients who weigh greater than 125% of their ideal body weight (IBW) will have 
their ATG dose calculated using adjusted  weight  according  to MCC -VCUHS  BMT  
Program  practice:  
 
Adjusted  Weight (KG)  = [(Weight - IBW)  × 0.4] +  IBW 
 
6.4.2 Premedications  for ATG 
 
ATG-related premedications  should be administered as follows:  
• Benadryl 50 mg IV, acetaminophen 650 mg PO, and methylprednisolone 
2 mg/kg  IV will be given  on each  day as a premedication for ATG. 
• Repeat the methylprednisolone at the same dose halfway through each ATG  
infusion . 
P
atients will be monitored according to standard procedures of the MCC -VCUHS  
BMT  Program  for infusion -related  side effects.  
MCC  Protocol  #: MCC -14-10739  25 Version #:3  
Version  Date:  09/22/2021   6.4.3 Total  Body  Irradiation (TBI) 
 
TBI will be administered twice on day -1 and once on the morning of day 0 with an 
AP-PA technique, prior to hematopoietic cell infusion. The total dose of radiation is  
450 cGy given in  3 fractions of  150 cGy/fraction and at  a dose  rate of  
10-15 cGy/minute prescribed at the midpoint (central axis). No lens or lung shielding  
will be us ed. 
 
6.5 Infection  Prophylaxis 
 
A standard  regimen  for infection  prophylaxis will  be followed as described  below  
beginning on day -9 (or earlier,  if necessary  per investigator’s  discretion) . 
Note:  Investigators  may substitute  appropriate  medications  for patients  who have an 
allergy  history  or if toxicities develop related  to the medications listed.  
• All patients  will receive:  
− Voriconazole 200 mg PO every 12 hours or 4 mg/kg IV every 12 hours; may be 
discontinued when tacrolimus is stopped. Patients intolerant of voriconazole may  
receive fluconazole 400 mg  PO daily.  
− Levofloxacin 500 mg/day  PO; continue  until neutrophil engraftment.  
− Bactrim  DS once  daily on 3 days  a week;  continue  for 6 months  post-transplant  
• For CMV -seropositive donor  or recipient:  
− Valacyclovir at 1000 mg TID for CMV prophylaxis; continue for 12 months  
post-transplant  
• For CMV -seronegative donor  and recipient:  
− Acyclovir  400 mg PO BID for HSV prophylaxis  
 
Appropriate therapeutic substitution may be made in the event of drug intolerance or 
toxicity.  
 
6.6 Transplant  
 
• Peripheral blood stem cells/bone marrow will be infused intravenously according to 
standard procedures for the BMT Program at MCC- VCUHS on day 0, after the last TBI  
treatment.  
• ABO -incompatible marrow  will be red-cell depleted.  
• Corticosteroids  will NOT  be routinely  used to support  cell infusion.  
MCC  Protocol  #: MCC -14-10739  26 Version #:3  
Version  Date:  09/22/2021   6.7 GVHD Prophylaxis 
 
Two agents, tacrolimus and MMF, will be used for GVHD prophylaxis in all patients as  
follows:  
 
6.7.1 Tacrolimus  
 
• Tacrolimus will be initiated orally at 0.04 mg/kg/day in divided doses beginning  
on day –2 and continuing until day 90 maintaining levels  of approximately  
10-14 ng/µL in the first month after transplant and 8- 12 ng/µL in the next 2  
months after transplant. Target tacrolimus levels may be adjusted for drug  
toxicity  at the investigator’s  discretion.  
 
• Tacrolimus taper will begin at day 90 over a 2 -month period at the transplanter’s  
discretion. The tacrolimus taper schedule may be modified by the transplant  
attending physician according to clinical judgment based on relapse or GVHD  
risk or  engraftment  status.  
 
6.7.2 MMF  
 
• MMF will be taken orally at a dose of 15 mg/kg BID; the patient’s adjusted  
weight  will be used for dose  calculation (see Section 6.4.1  for the formula  for 
calculating adjusted weight).  
• The dose  may be rounded to the nearest  capsule size (250 mg). 
• If the patient cannot tolerate oral MMF, MMF may be administered IV using an 
equivalent  IV dose.  
• The duration of MMF will  be per randomized cohort.  
 
− Patients  randomized to the investigational  cohort  (MMF -15) will  take MMF  
from day 0 to day 15. 
− Patients randomized to the control cohort (MMF- 30) will take MMF from day  
0 to day 30. 
 
The randomized assignments for the duration of MMF and for the post -transplant  
cytokine  support  are illustrated in  Figure  3. 
MCC  Protocol  #: MCC -14-10739  28 Version #:3  
Version  Date:  09/22/2021   6.9 Treatment  of Acute GVHD 
• Treatment of > grade II acute GVHD (see Section 10.6) will be initiated promptly with  
methylprednisolone until control is obtained, which will be determined by the 
investigator.  
• Patients with steroid- refractory acute GVHD will be treated according to standard 
GVHD therapy  protocols  for the MCC -VCUHS  BMT Program.  
 
6.10 Post -Treatment  Evaluation  
• All patients will undergo standard blood tests for granulocyte and T- cell chimerism at  
approximately  2, 4, 6, 8, 12,  24, and 52 weeks  following  transplant.  
• Flow cytometry to assess monocytes, T- cell subset, B cell, and NK cell recovery will be 
performed at 4, 8, 12, 24, and 52 weeks post -transplant. These assessments will also 
be performed  at weeks 2,  6, and 10 for the correlative studies (Section  1.7). 
• Relevant and disease- specific restaging studies will be performed per standard 
procedures of the MCC -VCUHS BMT Program following transplantation at 
approximately  3, 6, and 12 months  post-transplant  or earlier  if clinically  indicated.  
 
6.11 Management  of Mixed Chimerism/Relapse  
 
6.11.1  Eligibility to Discontinue Immunosuppression and Administer DLI or Other  
Intervention 
 
Patients demonstrating ≤ 90% donor chimerism (mixed chimerism) at any time point  
beyond approximately 8 weeks post- transplant and patients with residual/relapsing  
disease on restaging studies in the absence of GVHD at any time following  
transplant, will be eligible to discontinue immunosuppression and receive DLI or  
other relapse prevention intervention such as azacitidine (AML patients), rituximab 
(CD20 -positive NHL), brentuximab (CD30- positive HL or ALCL), or lenalidomide 
(MM) along with tapering of tacrolimus at investigator discretion. For patients at high 
risk for relapse,  relapse  prevention therapy  may be given after  day 60. 
 
Immunosuppression should be stopped or tapered before administration of DLI. DLI  
may be given the day following cessation of immunosuppression at the discretion of  
the investigator.  
 
Active (i.e., ongoing or unresolved) grade 3 acute GVHD  or moderate chronic  
GVHD is a contraindication for DLI. Caution should be exercised in DLI  
administration to patients with a previous history of steroid- refractory GVHD and 
grade III-IV active  GVHD as well as extensive chronic GVHD.  
MCC  Protocol  #: MCC -14-10739  29 Version #:3  
Version  Date:  09/22/2021   6.11.2  Donor  Lymphocyte Infusion (DLI)  
• Donor lymphocytes will be collected with either G -CSF or without any  
stimulation,  using  standard apheresis  techniques.  
• In the absence of disease relapse,  the first infusion  will generally  consist of 
5 x106 CD3+ cells /kg recipient  body weight. Dose escalation from 1 to 10 x107 
CD3+ cells /kg is allowed for subsequent infusions. Four to 8 weeks will be 
allowed  between infusions.  
• Chimerism  studies  will be obtained  at 4 weeks  following DLI,  and as clinically  
indicated thereafter.  Disease  restaging will  be done as clinically  indicated.  
 
6.12 Graft  Failure  
 
Patients  with failure to engraft  the allogeneic  stem  cell graft beyond day 28 (or earlier  at 
the discretion of the investigator) will be eligible to receive a hematopoietic stem cell (HSC)  
boost  from the donor.  
 
6.13 Additional  Treatment  Modalities  
 
• Medications  for the prevention of GVHD, other  than those specified in this protocol,  are 
not permitted.  
• Appropriate therapeutic substitution for other transplant -related interventions may be 
made  in the event  of drug intolerance  or toxicity.  
 
6.14 General  Concomitant  Medication  and Supportive Care  Guidelines  
 
Standard transplant -related supportive medications, other than non- protocol medications  
for the prevention of GVHD and cytokine support, may be administered at the 
investigator’s  discretion.  
 
6.15 Follow -Up Period  
 
The patient’s follow -up status will be recorded in the source documents and the CRFs.  
Study  follow -up will be conducted  as follows:  
 
6.15.1  Evaluation of Adverse Events  (AEs)  
 
Patients will continue to be evaluated for AEs until 6 months post -transplant or until  
the time of  relapse,  whichever  occurs  first. 
 
6.15.2  Relapse- Free Survival  
 
Follow -up for relapse- free survival will continue for 5 years following transplantation 
per standard post-transplant  procedures  or until subsequent  transplant or  death.  
 
6.15.3  Survival  
 
Patients  will be followed for survival  for 5 years.  
MCC  Protocol  #: MCC -14-10739  30 Version #:3  
Version  Date:  09/22/2021  7 DOSING  DELAYS/DOSE MODIFICATIONS  
There are no study -required dosing delays or dose modifications for any of the agents  
included in the SCT preparatory, GVHD prophylaxis, infection prophylaxis, or transplantation 
regimens. Dose modifications and delays, if needed for patient support and safety, will be 
per investigator  discretion.  
8 ADVERSE EVENTS: DEFINITIONS AND REPORTING  
REQUIREMENTS  
8.1 Definitions  
8.1.1 Adverse Event  (AE) 
AE means any untoward medical occurrence associated with the use of a drug in humans,  whether  or not considered drug related.  
8.1.2 Serious  AE (SAE)  
An AE is considered “serious” if, in the view of the investigator, it results in any of  
the following  outcomes:  
•death,
•a life -threatening AE (An AE is consider “life -threatening” if, in the view of the
investigator, its occurrence places the patient at immediate risk of death. It does
not include an AE that, had it occurred in a more severe form, might have
caused death.),
•inpatient  hospitalization or prolongation of existing  hospitalization,
Planned inpatient hospitalizations are exempt from SAE reporting. Eventsthat prolong hospitalization beyond the expected period of time and otherwisemeet  reporting  criteria  are, however, subject  to SAE reporting requirements.
•a persistent or significant incapacity or substantial disruption of the ability to
conduct  normal life  functions,  or
•a congenital  anomaly/birth defect.
Important medical events that may not result in death, be life- threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical  
judgment, they may jeopardize the patient and may require medical or surgical  
intervention to prevent  one of the outcomes  listed  in this  definition. 
MCC  Protocol  #: MCC -14-10739  31 Version #:3  
Version  Date:  09/22/2021  8.1.3 Unanticipated Problem  (UP) 
Unanticipated problems include any incident, experience, or outcome that meets all  
of the following  criteria: 
•unexpected (in terms of nature, severity, frequency) given (a) the research
procedures that are described in the protocol -related documents, such as the
IRB-approved research protocol and informed consent document; and (b) the
characteristics of the patient  population being st udied;
•related or possibly related to participation in the research (possibly related
means there is a reasonable possibility that the incident, experience, or outcomemay have been  caused by the procedures  involved in the research);  and
•suggests that the research places patients or others at a greater risk of harm
(including physical, psychological, economic, or social harm) than was
previously  known or  recognized.
8.1.4 AE Description  and Grade  
The descriptions and grading scales found in the revised Common Terminology  
Criteria for Adverse Events version 4.0 (CTCAE v4.0) will be utilized for AE  
reporting.  
8.1.5 AE Expectedness  
AEs can be ‘Unexpected’ or ‘Expected’. Refer to Section 8.2  regarding expected 
AEs. Unexpected AEs are those AEs occurring in one or more patients participating  
in the study,  the nature,  severity, or  frequency  of which  is not consistent with either:  
•The known or foreseeable risk of AEs associated with the procedures  involved
in the research that are described in (a) the protocol -related documents, such as
the IRB -approved research protocol and the current IRB -approved informed
consent document, and (b) other relevant sources of information, such as
product  labeling  and package  inserts;  or
•The expected natural progression of any underlying disease, disorder, or
condition of the patient(s) experiencing the AE and the patient’s predisposing
risk factor  profile  for the AE.
8.1.6 AE Attribution  
•Definite  – The AE is clearly related  to the study  intervention.
•Probable – The AE is likely  related  to the study  intervention.
•Possible  – The AE may be related to the study  intervention.
•Unlikely  – The AE is doubtfully  related  to the study  intervention.
•Unrelated – The AE is clearly NOT  related to the study  intervention.
MCC  Protocol  #: MCC -14-10739  32 Version #:3  
Version  Date:  09/22/2021  8.2 Known AEs Related to MMF, GM-CSF,  and G- CSF 
Patients randomized to the investigational cohort will receive MMF and GM -CSF. The 
control cohort will receive MMF and G -CSF. All 3 agents are routinely used in the clinical  
management of patients  undergoing SCT. Refer to the current FDA- approved prescribing  
information  for MMF,  GM-CSF,  and G-CSF.  
8.3 Recording AEs,  SAEs,  and UPs 
All AEs to be collected per protocol, all SAEs, and all UPs will be recorded per standard 
practice in the MCC -VCUHS BMT Program. In most cases, it is acceptable to record only  
the highest grade of a toxicity occurring during a particular study segment when an event  
has serial  fluctuations  in grade over  time.  
SAE’s will be entered into the OnCore SAE domain. UPs will be ent ered into the OnCore 
Deviations domain. An SAE that is both an SAE and a UP will be entered in both domains.  
For all SAEs, a corresponding entry should be made in the routine AE record to match the 
event entries in the SAE domain. Additionally, events related to stopping criteria will be entered  in OnCore as an  event  of special  interest.  
8.4 Time  Period and Grade  of AE  Capture 
AEs ≥ grade 3 including those expected with SCT (e.g., diarrhea, hematuria, hemorrhage,  
hypoxia, sepsis, mental status changers, pneumonitis, and veno- occlusive disease) will be 
recorded for study tabulation and analysis beginning on day 0 and continuing until day 180.  
Exception: Expected ≥ grade 3 cytopenias and changes in electrolytes (e.g., magnesium,  
potassium,  phosphorus,  and calcium)  will not be recorded.  
Toxicity assessments will include a review of all toxicities experienced during each  
assessment period.  The highest  grade  of each ≥ grade 3 toxicity  will be recorded.  
8.5 AEs Requiring Expedited Reporting  
All patients in this study will be receiving potentially toxic preparative therapy, therefore,  
significant  regimen -related toxicity  is anticipated,  i.e., expected AEs.  
8.5.1 Expedited Reporting  Requirements  
All grade 3, 4, and 5 unexpected AEs regardless of attribution will be reported in an 
expedited manner  from the first dose of MMF  (on day 0) until  post-transplant day  
180. (Refer  to Section  8.5.2 for AEs that should NOT  be considered unexpected.)
MCC  Protocol  #: MCC -14-10739  34 Version #:3  
Version  Date:  09/22/2021   9 PHARMACEUTICAL INFORMATION 
Refer to the current FDA-approved prescribing information for the pharmaceutical  
information for all of the agents, including MMF, GM -CSF, and G -CSF, used in the  
management  of patients  enrolled on the study.  
 
10 MEASUREMENT OF EFFECT 
10.1 Engraftment  
 
Hematopoietic  engraftment  is defined as all of the following: 
• Recovery  from post-transplant  cytopenia with an absolute neutrophil count  
of ≥ 0.5 x 109 /L for 3 consecutive measurements  or ≥ 1.0 x 109 /L for 1 day; 
• Platelet  count  of ≥ 20 x 109 /L for 7 days  without  transfusion;  and 
• Evidence by chimerism studies that hematopoiesis is of donor origin (≥ 95% donor  
DNA  by short  tandem  repeat  (STR)  analysis  in whole  blood,  myeloid, and lymphoid 
lineages).  
 
10.2 Complete Remission 
 
Complete remission is defined as engraftment along with attainment of a normocellular  
marrow with trilineage hematopoiesis and without evidence of residual disease by  
conventional, cytogenetic, or molecular criteria (i.e., flow cytometry, fluorescence in situ 
hybridization [FISH], and polymerase chain reaction [PCR] f or relevant disease- specific  
markers). CT scans should demonstrate normalization with any residual masses being  
negative by PET scanning in patients with lymphoma. Patients with myeloma should have 
a negative immunofixation.  
 
10.3 Length of Relapse- Free/DLI -Free Survival  and Survival  
 
All study patients including those removed from the treatment protocol will be followed for  
survival  every  3 months.  
• Length of relapse- free/DLI -free survival is measured from transplant to relapse, DLI,  
death,  or time of last contact,  censoring for  patients  alive and 
relapse- free/DLI -free at the time of last contact.  
 
• Length of survival is measured from transplant to death or time of last contact,  
censoring  for patients alive at  time of  last contact.  
 
10.4 Treatment  Failure  
 
Treatment failure is defined as death from toxicities associated with transplant procedure,  
relapse or progression of malignancy, or autologous hematopoietic recovery with loss of  
donor  chimerism.  
MCC  Protocol  #: MCC -14-10739  37 Version #:3  
Version  Date:  09/22/2021  11.4 Labeling  for all Blood  Samples  
Each  collected  blood sample  should be labeled as follows:  
•Study  number
•Patient  study  identification number
•Date  of sample  collection
•Time  of sample  collection
•Study  time point
11.5 Processing of Blood Samples  
Samples will be processed, stored, and cataloged by TDAAC until the appropriate time for  
T-cell sequencing, which will be performed by a commercial laboratory selected for the
study.
12 STUDY  CALENDAR  
12.1 Prior  to Randomization  
The hospital admission date and other treatments related to the transplant should be 
scheduled prior  to randomization.  
12.2 Following  Randomization 
Treatment  should  be initiated as soon  as possible  after randomization.  
12.3 Study  Calendar  
Study -required assessments, tests, and collection of blood samples for correlative studies  
are outlined on  Table 4 . 
MCC  Protocol  #: MCC -14-10739  39 Version #:3  
Version  Date:  09/22/2021  Table 4 Footnotes: 
A.In addition to the assessments/tests listed on Table 4, other tests and exams may be performed per standard guidelines for the MCC -VCUHS
BMT  Program  and per investigator discretion.
B.Timing  prior to randomization should be consistent  with the usual  MCC -VCUHS  BMT  Program  practices  to screen patients  for SCT.
C.Following hospital discharge, assessments/tests should be performed within +/ - 1 week of the day indicated on the calendar until 6 months;
then +/ - 3 weeks.
D.For patients who are not able to return for  evaluation during  years  3-5, follow -up may  be performed by telephone  contact  with the patient  or
through the patient’s referring physician.
E.Donor  and recipient.
F.Frequency  per standard practice  of the MCC -VCUHS  BMT Program.
G.Blood  chemistries  include serum creatinine,  total bilirubin,  alkaline  phosphatase,  AST,  ALT,  and additional  tests  per investigator  discretion.
H.Blood  chemistries  performed twice  weekly  until hospital  discharge;  performed weekly  after hospital  discharge  until weekly  testing  is no longer
indicated  per investigator assessment.
I.For WCBP:  At baseline (prior  to study  enrollment),  serum  pregnancy  test within  30 days  prior to initiation  of the preparatory  regimen.
J.Infectious  disease markers  include:  CMV,  EBV,  Hepatitis  panel  (HepA  Ab, HepB  SAb,  HepB  SAg,  HepB  Core Ab,  HepC  Ab), herpes  simplex
virus,  syphilis,  HIV-1 and - 2 and  HTLV -I and –II antibody,  varicella  zoster, and  toxoplasmosis.
K.Cardiac  assessments  include  ECG  and left ventricular  ejection fraction  or shortening fraction  by echocardiogram  or MUGA.
L.Pulmonary  function  tests  include  DLCO  (adjusted for hemoglobin),  FEV1,  and FVC.
M.Relevant  and disease- specific  staging according to the MCC -VCUHS  BMT  Program usual  practice.
N.Refer  to Section 8 for AE reporting requirements  and instructions.
O.Performed weekly until Day 63 post -transplant and as indicated on the calendar; assessment will include review of all abnormalities
experienced during  entire  assessment  period;  highest  grade  for each abnormality  (whether  attributed  to GVHD  or not) will be recorded on the
appropr iate CRF.
P.Granulocyte  and T-cell chimerism.  (Chimerism  pre-transplant  is donor/recipient  genotyping to allow  for chimerism  determination after
transplant.)
Q.Blood  samples  for flow cytometry:  T-cell subset,  B cells,  NK cells.
R.Blood  samples  collected  at weeks  2, 6, and 10 will be used for correlative studies  (see Section  11).
S.Blood  samples  collected  for future T- cell receptor  sequencing (see Section  11).
T.Baseline sample: after study registration but  before SCT; per investigator discretion, the specific timing for collection of the 30- and 100- day
samples  can be adjusted based on the patient’s  clinical status;  if GVHD is  diagnosed,  the sample should be collected as soon as possible.
MCC  Protocol  #: MCC -14-10739  40 Version #:3  
Version  Date:  09/22/2021  13 STATISTICAL  CONSIDERATIONS  
13.1 Randomization  Scheme 
To allocate consented and enrolled patients between treatments, we propose an outcome- 
adaptive allocation scheme that would increase the probability  that patients  are allocated 
to the more  effective  treatment  regimen.  We propose the use of the  doubly  adaptive biased 
coin design (DBCD) ( 36) coupled with optimal allocation of continuous outcomes, which 
has been shown to more greatly reduce treatment failures than other adaptive strategies  
while simultaneously maintaining power ( 37). In this set -up, the allocation probability for  
treatment  A (MMF -15) is the function  
𝑛𝑛𝑛𝑛 𝑛𝑛𝑛𝑛𝐴𝐴𝐴𝐴� 2 /𝜌𝜌𝜌𝜌
  𝐴𝐴𝐴𝐴 � 𝑛𝑛𝑛𝑛�  𝑔𝑔𝑔𝑔 � , 𝜌𝜌𝜌𝜌� = , 𝑛𝑛𝑛𝑛 𝑛𝑛𝑛𝑛𝐴𝐴𝐴𝐴� 2/𝜌𝜌𝜌𝜌 + �𝑛𝑛𝑛𝑛𝐵𝐵𝐵𝐵�2 /(1 − 𝜌𝜌𝜌𝜌) 
� 𝑛𝑛𝑛𝑛� 𝑛𝑛𝑛𝑛� 
where  𝑛𝑛𝑛𝑛𝐴𝐴𝐴𝐴 is the number  of patients  currently  allocated  to treatment  “A”, n is the total 
number  of currently  accrued patients,  ρ is the optimal  allocation ratio defined  as: 
 
𝑠𝑠𝑠𝑠𝐴𝐴𝐴𝐴�𝑥𝑥𝑥𝑥̅𝐵𝐵𝐵𝐵 
𝜌𝜌𝜌𝜌 = �𝑠𝑠𝑠𝑠𝐴𝐴𝐴𝐴�𝑥𝑥𝑥𝑥̅𝐵𝐵𝐵𝐵 +
𝑠𝑠𝑠𝑠𝐵𝐵𝐵𝐵�𝑥𝑥𝑥𝑥𝐴𝐴̅ 
1/2, 𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜ℎ𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑠𝑠𝑠𝑠𝑒𝑒𝑒𝑒, 𝑒𝑒𝑒𝑒𝑖𝑖𝑖𝑖 (𝑥𝑥𝑥𝑥𝐴𝐴 < 𝑥𝑥𝑥𝑥̅𝐵𝐵𝐵𝐵  𝑎𝑎𝑎𝑎𝑛𝑛𝑛𝑛𝑎𝑎𝑎𝑎 𝑒𝑒𝑒𝑒 > 1 )𝑜𝑜𝑜𝑜𝑒𝑒𝑒𝑒 (𝑥𝑥𝑥𝑥𝐴𝐴 > 𝑥𝑥𝑥𝑥̅𝐵𝐵𝐵𝐵 𝑎𝑎𝑎𝑎𝑛𝑛𝑛𝑛𝑎𝑎𝑎𝑎 𝑒𝑒𝑒𝑒 < 1) 
  
where  𝑒𝑒𝑒𝑒 = 
𝑠𝑠𝑠𝑠𝐴𝐴𝐴𝐴�𝑥𝑥𝑥𝑥𝐴𝐴 /𝑠𝑠𝑠𝑠𝐵𝐵𝐵𝐵�𝑥𝑥𝑥𝑥̅𝐵𝐵𝐵𝐵, and 𝑠𝑠𝑠𝑠𝑗𝑗𝑗𝑗  and 
𝑥𝑥𝑥𝑥𝑗𝑗 are the sample  standard  deviation and sample 
mean,  respectively,  in the jth treatment.  
Thus,  the allocation probability  for treatment  B (MMF -30) is: 
𝑔𝑔𝑔𝑔 𝑛𝑛𝑛𝑛𝐵𝐵𝐵𝐵�   , 𝜌𝜌𝜌𝜌� = 1 − 𝑔𝑔𝑔𝑔  𝑛𝑛𝑛𝑛𝐴𝐴𝐴𝐴�   , 𝜌𝜌𝜌𝜌�.
� 𝑛𝑛𝑛𝑛 � 𝑛𝑛𝑛𝑛 
The treatment -specific, day -60 ddCD3 count ( 33) will be the continuous measure used in 
the adaptive allocation algorithm listed above, with implications that, as the trial  
progresses, patients will be increasingly likely to be allocated to the treatment with larger  
mean ddCD3 count, provided a difference exists between the 2 groups. A two- patient  
lead- in will be used in both groups, where the allocation ratio is held constant (1:1) until at  
least  2 patients  have provided their day-60 ddCD3 measurements  in each  group;  this will 
ensure the mean and standard deviations for each group are estimable. As large treatment  
differences in mean ddCD3 counts between the 2 treatment groups could lead to 
imbalanced treatment groups, we will perform additional statistical analyses (described 
below) using patient information from the previous ATG TBI trial whose treatment regimen 
is identical  to that in the MMF -30 group.  Note  that we anticipate patients  allocated to  
MCC  Protocol  #: MCC -14-10739  41 Version #:3  
Version  Date:  09/22/2021  MMF -30 will have inferior ddCD3 counts compared to patients allocated to MMF- 15, on 
account of the earlier cessation of MMF at day 15 in the MMF- 15 group as opposed to day  
30 in the control  cohor t in this study  (MMF -30) and as in the previous study  (MCC -11561).  
MCC  Protocol  #: MCC -14-10739  42 Version #:3  
Version  Date:  09/22/2021  13.2 Stratification Factors  
Patients  will be stratified at the time of randomization according  to the following  factors:  
•Diagnosis  (Hodgkin  lymphoma,  NHL, ALL,  CLL or MM or AML,  CML, MDS)
•Donor  type (MRD  or URD)
Adaptive allocation rates will be determined separately within each level/combination of the 
stratification  factors.  
13.3 Statistical  Methods  
13.3.1 Primary  Endpoint  
The primary outcome in this study is event -free survival, where the conditional 
events are the occurrence of relapse or  DLI. 
13.3.2 Secondary  Endpoints  (with  measurement  type)  
•Overall  survival  (days  to event  or survival:  time-to-event;  survival:  categorical)
•Acute and chronic GVHD (days to positive diagnosis: time- to-event ; positive
diagnosis:  categorical)
•Engraftment  loss (days  to loss: time-to-event;  graft loss: categorical)
•Engraftment  syndrome (categorical)
•Immune reconstitution (numerical)
•DLI administration (days to administration: time -to-event; administration:
categorical)
•Rate  of T-cell recovery  following SCT
13.3.3 Statistical  Analysis  
The difference in the survival  rate between patients  allocated to MMF -30 and 
MMF -15 will be tested using a log- rank test and will be graphically represented with 
a Kaplan- Meier step- function for each treatment group; all time -to-event outcomes  
will be similarly analyzed and will account for the competing hazard of fatality using  
Gray’s test ( 38). Odds ratios of successful treatment for categorical outcomes  
between the 2 treatment groups will be estimated using logistic regression with a 
two-group treatment indicator. Treatment -specific means of numerical  
measurements will be compared between treatment groups using a one -factor  
analysis of  variance m odel with  2 levels.  
To account for patient demographics and other characteristics, a proportional  
hazards model will be used for time- to-event measurements, multiple logistic  
regression will be used for categorical outcomes, and analysis of covariance wil l be 
used for numerical  outcomes.  For repeated -measure numerical  outcomes  
(e.g., immune reconstitution), mixed- effect repeated- measure analysis of variance 
will be used,  where a patient -level random  effect  will be used to account  for intra - 
MCC  Protocol  #: MCC -14-10739  43 Version #:3  
Version  Date:  09/22/2021  subject dependence, which will be modeled with an autoregressive correlation 
structure.  All categorical measures will be summarized  with frequencies,  
proportions, and 95% confidence intervals for each treatment group, and odds ratios  
will also be reported.  All numerical measures will be summarized with means, and 
95% confidence  intervals, and  standard  deviations  for each  treatment  group.  
Summary measures (proportions, means) and analytic measures (odds ratios,  
differences in means, hazard ratios) will also be adjusted for patient demographics  
and characteristics. 
All analyses will be conducted in the manner described above in 2 different  
scenarios:  (i) including only patients  accrued  within  this study  period,  and 
(ii)including both patients accrued within this study period as well as those allocated
to the 5.1- dose group of the previous study (MCC -11561) (n=19). These additional
patients will be included in the MMF- 30 treatment group, and all analyses will be
adjusted by a random cohort effect to account for any  between- study differences.
These secondary analyses with additional patients will have greater power (see
below) than analyses featuring patients solely from the current study, and will help
protect against any imbalances caused by the outcome- adaptive al location
mechanism.
Additionally,  we will  conduct  a sub-set analysis  consisting of the following:  
(1)patients diagnosed with multiple myeloma (MM) in both the MMF- 15 and
MMF -30 groups  who have relapsed;  (2) a group  of historical  control  patients  with
MM who have relapsed but have never received an allogeneic transplant. We
assume  that nearly  1/3 of the 60 patients in the current  study  (n ≈ 20) will be
diagnosed with MM. The historical control group will consist of 20 patients matched
for age, gender and race.  The difference in the survival rate between patients who
received an allogeneic transplant (treated at either MMF- 15 or MMF- 30) and the
group of historical control patients will be tested using a log -rank test and will be
graphically  represented  using a K aplan- Meier  step function  in each  group.
13.4 Sample Size and Power  Determination  
The following calculations assume that 12 patients will be accrued per year for 5 years (60 
total), that there will be twice the allocated patients (due to the outcome- adaptive allocation 
algorithm) in the MMF- 15 group than in the MMF -30 group, and an event rate of 0.421 
(observed rate at 2 years in the MMF- 30 group in the previous study [MCC -11561]). Then 
assuming a 15% reduction in the event rate in the MMF- 15 group, we will have 80% power  
(at 10% significance) to detect a hazard ratio as small as 1.53.  If we add the patient  
information from the previous study into the MMF- 30 group (which would help balance the 
expected sample sizes between treatment groups), then we will have 80% power to detect  
a hazard ratio as  small as  1.50.  
13.5 Stopping Criteria  
The early stopping criteria will be applied to each treatment group separately once 5 
patients within a group have been accrued. The study will be stopped early if the observed 
number of patients experiencing one of the 4 events listed on Table 5 exceeds the 
threshold number of events  (see Figure 4 and Figure 5 ), where the threshold  number  of 
MCC  Protocol  #: MCC -14-10739  45 Version #:3  
Version  Date:  09/22/2021   The events  comprising  the stopping rule will be defined  as: 
• Engraftment failure defined as loss of established donor chimerism or failure to 
establish stable mixed donor chimerism, with or without autologous reconstitution,  
despite withdrawal of immunosuppression and DLI beyond day 100. In the absence of  
progressive disease, an observation period of 8 weeks post DLI will be required prior to 
declaring engraftment  failure.  
• Steroid- refractory GVHD defined as biopsy -proven ≥ grade III classic acute GVHD  
(developing before day 100) requiring  therapy  with systemic corticosteroids  for 
> 1 week  for control.  
• Treatment -related day 100 mortality,  excluding  relapse/progressive disease,  
i.e., GVHD,  sepsis, VOD,  pneumonitis,  etc. 
• Severe engraftment syndrome, defined as fever, rash, hypoxia, pneumonitis, and  
diarrhea requiring therapy with corticosteroids (methylprednisolone > 2 mg/kg/day) or  
etanercept.  
 
Patients unable to receive protocol- specified conditioning and GVHD prophylaxis will be 
excluded from the analysis for early stopping criteria. For example, patients unable to  
receive either tacrolimus or MMF will not count towar ds engraftment failure and GVHD  
analysis. Likewise, the stopping rule for engraftment failure and treatment -related mortality  
requires  that the patients  included in the analyses be transplanted.  
 
14 DATA  AND  SAFETY  MONITORING  PLAN (DSMP)  
The DSMP  for this study  will consist of the  following  3 elements:  
 
14.1 Study  Team  
 
The study team minimally consists of the principal investigator, the co- investigators, the 
study coordinator, the clinical research associate, and the study biostatistician. While patients are on treatment, the principal investigator, the study coordinator, and the clinical  
research associate will meet at least monthly and will meet at least quarterly with the study  
biostatistician to review study status. This review will include, but not be limit ed to,  
reportable AEs and UPs, and an update of the ongoing study summary that describes  
study progress in terms of the study schema. The appropriateness of further patient  
enrollment  is addressed.  All meetings  including  attendance are documented.  
 
14.2 Audit  Committee  
 
This trial will be audited by the MCC  Audit  Committee.  
 
14.3 Data  and Safety  Monitoring Committee  (DSMC) 
 
The study will be monitored by the MCC DSMC. The frequency with which the protocol is  
reviewed will be determined by the Protocol  Review  and Monitoring  Committee.  
MCC  Protocol  #: MCC -14-10739  46 Version #:3  
Version  Date:  09/22/2021   15 REGULATORY  COMPLIANCE  AND  ETHICS  
15.1 Ethical  Standard  
 
This study will be conducted in conformance with the principles set forth in The Belmont  
Report: Ethical Principles and Guidelines for the Protection of Human Subjects of 
Research (US National Commission for the Protection of Human Subjects of Biomedical  
and Behavioral Research,  April 18, 1979).  
 
15.2 Regulatory  Compliance  
 
This study  will be conducted in compliance with: 
• The protocol  
• Federal regulations, as applicable, including: 21 CFR 50 (Protection of Human 
Subjects/Informed Consent); 21 CFR 56 (Institutional Review Boards); 21 CFR 312 
(IND Application); and 45 CFR 46 Subparts A (Common Rule), B (Pregnant Women,  
Human Fetuses and Neonates),  C (Prisoners),  and D (Child ren) 
 
15.3 Institutional  Review  Board  
 
The VCU  IRB, which  is registered  with the Office  for Human  Research Protections  
(OHRP), will review and provide approval for the protocol, the associated informed consent  
document, material that will be provided to participating patients, and any recruitment  
material. Any amendments to the protocol, consent form, or other materials will also be approved by  the IRB. 
 
15.4 Informed Consent  Process 
 
Informed consent  is a process  that is initiated  prior to the individual’s  agreeing  to 
participate in the study and continues throughout the individual’s study participation.  
Extensive discussion of risks and possible benefits of this therapy will be provided to the  
patients and their families. Consent forms describing in detail the study interventions/  
products, study procedures, and risks are given to the patient and written documentation of  
informed consent is required prior to starting intervention/administering study product. The consent form will be IRB -approved and the patient will be asked to read and review the 
document. Upon reviewing the document, the investigator will explain the research study to 
the patient and answer any questions that may arise. The patient will sign the informed 
consent document prior to any procedures being done specifically for the study. The 
patients should have the opportunity to discuss the study with their surrogates or think  
about it prior to agreeing to participate. Patients may withdraw consent at any time throughout the course of the trial. A copy of the informed consent document will be given to 
patients for their records. The rights and welfare of the patients will be protected by  
emphasizing to them that the quality of their medical care will not be adversely affected if  
they decline to participate in this  study.  
MCC  Protocol  #: MCC -14-10739  47 Version #:3  
Version  Date:  09/22/2021   15.5 Patient  Confidentiality  and Access to Source  Documents/Data  
 
Patient confidentiality is strictly held in trust by the participating investigators and their staff.  
This confidentiality includes the clinical information relating to participating patients, as well  
as any  genetic  or biological testing.  
 
The study protocol, documentation, data, and all other information generated will be held in 
strict confidence. No information concerning the study or the data will  be released to any  
unauthorized third party  without prior  written  approval  of the principal  investigator.  
 
The principal investigator will allow access to all source data and documents for the purposes of  monitoring,  audits,  IRB review,  and regulatory  inspections.  
 
The study monitor or other authorized representatives of the principal investigator may  
inspect all documents and records required to be maintained by the investigator, including  
but not limited to, medical records (office, clinic, or hospital) and pharmacy records for the patients in  this study.  The clinical study  site will permit access to such records.  
 
16 DATA  HANDLING  AND  RECORD KEEPING 
16.1 Data  Management  Responsibilities  
 
The principal  investigator  is responsible for: (i) the overall  conduct of the investigation;  
(ii) ongoing review of trial data including all safety reports; and (iii) apprising participating  
investigators of any UPs. Participating investigators are responsible for reporting SAEs and 
UPs as  required in Section 8. 
 
Any laboratory conducting correlative studies must maintain the laboratory records and 
documentation (laboratory notebooks, laboratory protocols, print -outs, recordings,  
photographs,  etc). 
 
16.2 Source Documents  
 
Source documents for clinical information (patient history, diagnosis, clinical and diagnostic  
test reports, etc) are maintained in the patient’s clinical file. Source documents for the correlative studies  are maintained in the laboratory  conducting  the study.  
 
16.3 Case Report  Forms  
 
Standard and study -specific case report forms (CRFs) will be used to capture all the  
information required by the protocol. The CRFs will be created and approved by the study  
team to ensure the most effective data acquisition. All information on the CRFs wi ll be 
traceable to the source documents which are generally maintained in the patient’s file. All  
CRFs should be completed and available for collection within a timely manner, preferably  
no more  than 7 days  after the patient’s  visit. 
MCC  Protocol  #: MCC -14-10739  48 Version #:3  
Version  Date:  09/22/2021   16.4 Study  Record Retention  
 
As applicable, study records will be maintained a minimum of 5 years beyond: (i) the 
publication of any abstract or manuscript reporting the results of the protocol; (2) the 
submission of any sponsored research final report; or (iii) submission of a final report to  
clinicaltrials.gov.  
MCC  Protocol  #: MCC -14-10739  49 Version #:3  
Version  Date:  09/22/2021   17 REFERENCES  
1. Henig I, Zuckerman T. Hematopoietic stem cell transplantation- 50 years of evolution 
and future perspectives. Rambam Maimonides Med J . 2014; 5:e0028.  
PMCID:PMC4222417.  
2. Gyurkocza  B, Sandmaier BM. Conditioning regimens for hematopoietic cell  
transplantation: One size does not fit all. Blood. 2014; 124:344- 353. 
PMCID:PMC4102707.  
3. Mikell JL, Waller EK, Switchenko JM, Rangaraju S, Ali Z, Graiser M, Hall WA, Langston 
AA, Esiashvili N, Khoury  HJ, Khan MK. Similar  survival  for patients  undergoing 
reduced- intensity total body irradiation (tbi) versus myeloablative tbi as conditioning for  
allogeneic  transplant  in acute  leukemia.  Int J Radiat  Oncol  Biol Phys . 2014;  89:360 -369. 
4. Dey BR, McAfee S, Sackstein R, Colby C, Saidman S, Weymouth D, Poliquin C,  
Vanderklish J, Sachs DH, Sykes M, Spitzer TR. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed 
hematologic malignancy following autologous stem cell transplantation. Biol Blood  
Marrow  Transplant . 2001;  7:604- 612. 
5. Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C, Maloney DG,  
Storb R. Comparing morbidity and mortality of hla -matched unrelated donor  
hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning:  Influence  of pretransplantation  comorbidities.  Blood. 2004;  104:961- 968. 
6. Dey BR, McAfee S, Colby C, Cieply K, Caron M, Saidman S, Preffer F, Shaffer J,  
Tarbell N, Sackstein R, Sachs D, Sykes M, Spitzer TR. Anti -tumour response despite 
loss of donor chimaerism in patients treated with non- myeloablative conditioning and 
allogeneic  stem  cell transplantation.  Br J Haematol . 2005;  128:351- 359. 
7. Baron F, Maris MB, Sandmaier BM, Storer BE, Sorror M, Diaconescu R, Woolfrey AE,  
Chauncey TR, Flowers ME, Mielcarek M, Maloney DG, Storb R. Graft -versus -tumor  
effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.  J Clin Oncol . 2005;  23:1993- 2003.  
8. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM,  
Maloney DG, Storer B, Lange T, Chauncey T, Deininger M, Ponisch W, Anasetti C,  
Woolfrey A, Little MT, Blume KG, McSweeney PA, Storb RF. Low -dose total body  
irradiation (tbi) and fludarabine followed by hematopoietic cell transplantation (hct) from  
hla-matched or mismatched unrelated donors and postgrafting immunosuppression with 
cyclosporine and mycophenolate mofetil (mmf) can induce durable complete chimerism  
and sustained remissions in patients with hematological diseases. Blood. 2003;  
101:1620- 1629.  
9. Russell JA, Turner  AR, Larratt  L, Chaudhry  A, Morris  D, Brown  C, Quinlan D, Stewart  
D. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to 
graft-versus -host disease: A matched pair analysis. Biol Blood Marrow Transplant . 
2007;  13:299 -306. 
MCC  Protocol  #: MCC -14-10739  50 Version #:3  
Version  Date:  09/22/2021   10. Duggan P, Booth K, Chaudhry A, Stewart D, Ruether JD, Gluck S, M orris D, Brown CB,  
Herbut B, Coppes M, Anderson R, Wolff J, Egeler M, Desai S, Turner AR, Larratt L,  
Gyonyor E, Russell JA, Alberta B, Bone Marrow Transplant P. Unrelated donor bmt  
recipients given pretransplant low -dose antithymocyte globulin have outcomes  
equivalent to matched sibling bmt: A matched pair analysis. Bone Marrow Transplant . 
2002;  30:681 -686. 
11. Portier DA, Sabo RT, Roberts CH, Fletcher DS, Meier J, Clark WB, Neale MC, Manjili  
MH, McCarty JM, Chung HM, Toor AA. Anti -thymocy te globulin for conditioning in 
matched unrelated donor hematopoietic cell transplantation provides comparable 
outcomes to matched related donor recipients. Bone Marrow Transplant . 2012;  
47:1513- 1519.  PMCID:PMC4912115.  NIHMSID:NIHMS793371.  
12. Kohrt  H, Lowsky  R. Nonmyeloablative conditioning with total lymphoid irradiation  and 
antithymocyte globulin: An update. Curr Opin Hematol . 2009; 16:460- 465. 
PMCID:PMC2925420.  NIHMSID:NIHMS224948.  
13. Benjamin J, Chhabra S, Kohrt HE, Lavori P, Laport GG, Arai S, Johnston L, Mi klos DB,  
Shizuru JA, Weng WK, Negrin RS, Lowsky R. Total lymphoid irradiation- antithymocyte 
globulin conditioning and allogeneic transplantation for patients with myelodysplastic  
syndromes and myeloproliferative neoplasms. Biol Blood Marrow Transplant . 2014;  
20:837- 843. PMCID:PMC4389687.  NIHMSID:NIHMS667687.  
14. Meier J, Roberts C, Avent K, Hazlett A, Berrie J, Payne K, Hamm D, Desmarais C,  
Sanders C, Hogan KT, Archer KJ, Manjili MH, Toor AA. Fractal organization of the human t cell repertoire in health and after stem cell transplantation. Biol Blood Marrow  
Transplant . 2013;  19:366 -377. 
15. Sampson JK, Sheth NU, Koparde VN, Scalora AF, Serrano MG, Lee V, Roberts CH,  
Jameson- Lee M, Ferreira- Gonzalez A, Manjili  MH, Buck GA, Neale MC, Toor AA.  
Whole exome sequencing to estimate alloreactivity potential between donors and recipients  in stem  cell transplantation.  Br J Haematol . 2014;  166:566 -570. 
16. Jameson- Lee M, Koparde VN, Sampson JK, Scalora AF, Khalid H, Sheth N,  Griffith P, 
Serrano MG, Lee V, Roberts CH, Neale MC, Buck GA, Manjili M, Toor AA. In silico 
derivation of hla- specific alloreactivity potential from whole exome sequencing of stem  
cell transplant donor -recipient pairs. Biol Blood Marrow Transplant . 2014; 20:S269- 
S270.  
17. Toor AA, Kobulnicky JD, Salman S, Roberts CH, Jameson- Lee M, Meier J, Scalora A,  
Sheth N, Koparde V, Serrano M, Buck GA, Clark WB, McCarty JM, Chung HM, Manjili 
MH, Sabo RT, Neale MC. Stem cell transplantation as a dynamical system: Are clinical 
outcomes  deterministic?  Front  Immunol . 2014; 5:613.  PMCID:PMC4253954.  
18. Toor AA, Sabo R, Salman SR, Moore B, Scalora AF, Aziz M, Kobulnicky J, Meier JA,  
Ali ASS, Manjili M, Song SY, Clark W, McCarty JM, Neale MC, Chung H, Roberts CH.  
Dynamical system modeling of immune reconstitution following allogeneic stem cell  
transplantation (sct) conditioned with rabbit anti -thymocyte globulin. Biol Blood Marrow  
Transplant . 2015;  21:S169- S170.  
19. Grant SM, Heel RC. Recombinant granulocyte- macrophage colony -stimulating factor  
(rgm-csf). A review of its pharmacological properties and prospective role in the 
management  of myelosuppression. Drugs . 1992;  43:516- 560. 
MCC  Protocol  #: MCC -14-10739  51 Version #:3  
Version  Date:  09/22/2021   20. Toor AA, Sabo RT, Roberts CH, Moore BL, Salman SR, Scalora AF, Aziz MT, Shubar  
Ali AS, Hall CE,  Meier J, Thorn RM, Wang E, Song S, Miller K, Rizzo K, Clark WB,  
McCarty JM, Chung HM, Manjili MH, Neale MC. Dynamical system modeling of immune 
reconstitution after allogeneic stem cell transplantation identifies patients at risk for  
adverse outcomes.  Biol Blood Marrow Transplant . 2015.  
21. Greenberg P, Advani R, Keating A, Gulati SC, Nimer S, Champlin R, Karanes C, Gorin NC, Powles RL, Smith A, Lamborn K, Cuffie C. Gm -csf accelerates neutrophil recovery  
after autologous hematopoietic stem cell transplantation. Bone Marrow Transplant . 
1996;  18:1057 -1064.  
22. Link H, Boogaerts MA, Carella AM, Ferrant A, Gadner H, Gorin NC, Harabacz I,  
Harousseau JL, Herve P, Holldack J, et al. A controlled trial of recombinant human 
granulocyte- macrophage colony -stimulating factor a fter total body irradiation, high- dose  
chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic  
leukemia  or malignant lymphoma.  Blood. 1992;  80:2188- 2195.  
23. Nemunaitis J, Rosenfeld CS, Ash R, Freedman MH, Deeg HJ, Appelbaum F, Singer  
JW, Flomenberg N, Dalton  W, Elfenbein  GJ, et al. Phase  iii randomized,  double- blind  
placebo- controlled trial of rhgm -csf following allogeneic bone marrow transplantation.  
Bone Marrow  Transplant . 1995;  15:949- 954. 
24. Trigg ME, Peters C, Zimmerman MB. Administration of recombinant human 
granulocyte- macrophage colony -stimulating factor to children undergoing allogeneic  
marrow  transplantation:  A prospective,  randomized,  double- masked,  placebo- controlled 
trial. Pediatr  Transplant . 2000;  4:123 -131. 
25. Ho VT, Mirza NQ, Junco Dd D, Okamura T, Przepiorka D. The effect of hematopoietic  
growth factors on the risk of graft -vs-host disease after allogeneic hematopoietic stem  
cell transplantation:  A meta -analysis.  Bone  Marrow  Transplant . 2003;  32:771- 775. 
26. Bacig alupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P,  
Oneto R, Bruno B, Barbanti M, Sacchi N, Van Lint MT, Bosi A. Antithymocyte globulin for graft -versus -host disease prophylaxis in transplants from unrelated donors: 2 
randomized studies from gruppo italiano trapianti midollo osseo (gitmo). Blood. 2001;  
98:2942- 2947.  
27. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T,  
Heim  DA, Schwerdtfeger  R, Kolbe K, Mayer  J, Maertens JA, Linkesch  W, Holler  E, 
Koza  V, Bornhauser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Socie G, A.  
TG-Fresenius Trial Group. Standard graft -versus -host disease prophylaxis with or  
without anti -t-cell globulin in haematopoietic cell transplantation from matched unrelated 
donors: A randomised, open- label, multicentre phase 3 trial. Lancet Oncol. 2009;  
10:855- 864. 
28. Kohrt HE, Turnbull BB, Heydari K, Shizuru JA, Laport GG, Miklos DB, Johnston LJ, Arai 
S, Weng WK, Hoppe RT, Lavori PW, Blume KG, Negrin RS, Strober S, Lowsky R. Tli  
and atg conditioning with low risk of graft -versus -host disease retains antitumor  
reactions after allogeneic hematopoietic cell transplantation from related and unrelated 
donors.  Blood. 2009;  114:1099- 1109.  PMCID:PMC2721787.  
MCC  Protocol  #: MCC -14-10739  52 Version #:3  
Version  Date:  09/22/2021  29.Soiffer RJ, Lerademacher J, Ho V, Kan F, Artz A, Champlin RE, Devine S, Isola L,
Lazarus HM, Marks DI, Porter DL, Waller EK, Horowitz MM, Eapen M. Impact of
immune modulation with anti-t- cell antibodies on the outcome of reduced -intensity
allogeneic hematopoietic stem cell t ransplantation for hematologic malignancies. Blood.
2011;  117:6963 -6970.  PMCID:PMC3128486.
30.Lowsky R, Takahashi T, Liu YP, Dejbakhsh- Jones S, Grumet FC, Shizuru JA, Laport
GG, Stockerl -Goldstein KE, Johnston LJ, Hoppe RT, Bloch DA, Blume KG, Negrin RS,
Strober S. Protective conditioning for acute graft -versus -host disease. N Engl J Med.
2005;  353:1321 -1331.
31.Toor A, Rodriguez T, Bauml M, Mathews H, Shanti S, Senitzer D, Kini A, Norton J,
Parthasarathy  M, Mohideen N, Petrowsky  C, Bonilla  B, Smith  S, Stiff P. Feasibility  of
conditioning with thymoglobulin and reduced intensity tbi to reduce acute gvhd inrecipients  of allogeneic sct.  Bone Marrow Transplant . 2008;  42:723- 731.
32.Thorn R, Meier J, Wang E, Sabo R, Scalora A, Roberts C, Song S, Manjili M, Clark W,McCarty J, Chung H, Toor A. Favorable t cell reconstitution in reduced intensity
conditioned allogeneic stem cell transplantation with low -dose rabbit anti- thymocyte
globulin  and total body  irradiation.  Blood. 2013;  122:4577.
33.Toor AA, Sabo RT, Chung HM, Roberts C, Manjili RH, Song S, Williams DC, Jr.,Edmiston W, Gatesman ML, Edwards RW, Ferreira- Gonzalez A, Clark WB, Neale MC,
McCarty JM, Manjili MH. Favorable outcomes in patients with high donor -derived t cell
count after in vivo t cell -depleted reduced -intensity allogeneic stem cell transplantation.
Biol Blood Marrow Transplant . 2012; 18:794- 804. PMCID:PMC4932864.
NIHMSID:NIHMS788145.
34.Jameson- Lee M, Koparde V, Griffith P, Scalora AF, Sampson JK, Khalid H, Sheth NU,
Batalo M, Serrano MG, Roberts CH, Hess ML, Buck GA, Neale MC, Manjili MH, Toor
AA. In silico derivation of hla- specific alloreactivity potential from whole exome
sequencing of stem -cell transplant donors and recipients: Understanding the
quantitative immunobiology o f allogeneic transplantation. Front Immunol . 2014; 5:529.
PMCID:PMC4222229.
35.Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA, Oette D,
Cassileth PA, Stadtmauer EA, Wiernik PH. A randomized placebo- controlled phase iii
study of granulocyte- macrophage colony -stimulating factor in adult patients (> 55 to 70
years of age) with acute myelogenous leukemia: A study of the eastern cooperativeoncology  group  (e1490).  Blood. 1995;  86:457- 462.
36.Eisele JR. The doubly adaptive biased coin design for sequen tial clinical- trials. J Stat
Plan Inference . 1994;  38:249- 261.
37.Zhang L, Rosenberger WF. Response- adaptive randomization for clinical trials with
continuous outcomes.  Biometrics . 2006; 62:562 -569.
38.Gray RJ. A class of k- sample tests for comparing the cumulative incidence of a
competing risk. Ann Stat. 1988; 16:1141- 1154.